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ABSTRACT
Svitlova, Olena B. M.S. Microbiology and Immunology Graduate Program, Wright State
University, 2019. Six-Nine Months Long Term Culture of Mouse Bone Marrow Cells
Differentiated to Macrophages and Eosinophils.

Mouse models of eosinophil-associated diseases have been used to study the
mechanisms of disease pathogenesis. In this study, mouse-derived bone marrow cells were
used in long-term (6 and 9 months) cell cultures of differentiated eosinophils and
macrophages. IL-5 was used to differentiate the stem cells to eosinophils and GM-CSF
was used to propagate macrophages from the bone marrow stem cells. The maximum time
period for observing the eosinophil cultures was 252 days which is censurably longer than
the 18 days culture period observed by others.
The results were assessed by describing the microscopic cell morphology by Wright
staining, modified Giemsa staining and protein expression by immunofluorescent staining.
The GMCSF-stimulated bone marrow cultures produced classically appearing
monocyte/macrophages throughout the study and were used to compare the development
of the eosinophils over the long-term period of observation.
Differentiation of the BM cells was carried out using with growth factors (SCF,
FLT3L) and cytokines (IL-5, GM-CSF) over the 252 days period. The most suitable
culture plate for long-term of cell growth were thee 60 mm petri dishes. At 252 days, the
eosinophils exhibited as bi-lobed nuclear shapes, comparable with human eosinophils.
Dendrite-like ramifications were observed on the surfaces of these eosinophils. Long term
iii

culture of eosinophils in the presence of IL-5 contributed to formation of eosinophil
extracellular traps (EETs) areas. Within the EETs the cells surface of eosinophils
developed holes; the nucleus of such cells lost the “ring-like” or “lobular” morphology and
appeared in de-condensed fashion. Within the EETs, the plasma membranes of eosinophils
developed the protrusions containing cytoplasmic granules. The EETs and protrusions had
not been observed previously in the mouse eosinophil models in vitro but were described
in human eosinophils. Consequently, the long-term culture of mouse bone-marrow derived
eosinophil cultures may be useful in identifying conditions leading to pathology of hypoeosinophilia human diseases such as asthma and bullous pemphigoid (BP).
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INTRODUCTION

Eosinophils are granulocytes that respond to Th2 cytokines, and different
chemokines that are elicited by helminth-associated infection and reactions of the
hypersensitivity (Rosenberg and Hogan, 2006).1 Rotman et al, 1996, have shown the low
account of eosinophils can support the survival of the parasites in mouse models.2
Eosinophils showed the protective role against viruses. In beginning of the respiratory
syncytial virus (RSV) infection the mediators secreted by eosinophils capable decrease the
viral infectivity (Domachowske et al, 1998).3 A recent study demonstrated the role of
human and mouse eosinophils as the targets for the RSV and pneumonia virus of mice
(PVM) and support the viral replication (Dyer et al, 2009).4 Thus, the total role of
eosinophils in response to the viral infection still are unknown and such “double game” of
eosinophils needs more investigations. The hypereosinophilia can contribute to the
development of different diseases such as asthma, eosinophilic esophagitis (EE),
eosinophilic myopathies and others (Rosenberg et al, 2013; Varga and Kahari, 1997).5-6
Within last decade it was demonstrated that the development of extracellular trap by
eosinophils (EETs) contribute to worsening of pathogenesis of the asthma, infectious skin
diseases, and autoimmune disorders Simon et al, 2011; Cortiens et al, 2010.7-8 The serious
impact on health with the high mortality represents development of Bullous pemphigoid
(BP) and with this case the eosinophils contribute the separation of the dermo-epiderma
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junction (DEJ) by formation of the EETs. The responses of eosinophils to the infections,
developing EET, and dependence of pathological disorders on the eosinophils need more
experimental data. Bocher and Gleich, 2010, demonstrated the role of the mouse modelsderiving eosinophils in the “recruitment, trafficking and function in relation to diseases”.9
The mouse and human eosinophils are similar to each other morphologically; however,
some granules’ functions are different and some surface antigens as well as response to the
chemoattractants are different also (Rosenberg et al, 2007).10 In recent time, the question
remains whether the eosinophils contribute to the development of autoimmune diseases,
allergies, as well as support parasitic and viral infection.
We hypothesize that long-term differentiation of eosinophils and macrophages
from the mouse bone marrow cells (BM) with contribution of the growth factors in
conjunction with cytokines might show the different morphology of cells and distinctive,
on standard conception, functions which respond to the environmental factors in vitro. To
test this hypothesis, we differentiated the eosinophils and macrophages from the mouse
BM cells with the help of FLT3L, SCF, and cytokines (IL-5 and GM-CSF). Standard
protocols were used for differentiating such cells and growing within 18 days; however,
the protocol for the long-term differentiation does not exist yet. A protocol must be
developed to extend the culturing time. Also, the specific recommendations for the freezing
cells was used and a previously mentioned protocol for the freezing-thawing regime.
Moreover, the results by Wright staining, Giemsa staining and Immunofluorescence
staining were demonstrated.
Based on our observations, 252 days of differentiation of eosinophils and
macrophages depended on the SCF, FLT as the GFs and cytokines. The necessity for the
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both GF was shown through declining of the confluences of eosinophils and macrophages
in the culture. The BM cells showed sharp reduction that were differentiated with GM-CSF
in the absence of it on day 60 and the confluence of the eosinophils was decreased with
absence of IL-5. Moreover, we had an unsuccessful attempt with the freezing-thawing
regimen of both cell lines when used the previously proposed protocol as well as an attempt
to use 6-well plates for the long-term growth purpose.
The morphology assesses of the differentiation of the BM cells to eosinophils of
was determined. Thus, we found the bi-lobular nucleus of eosinophils after 50 days of the
cells’ culture and dendrite-like ramifications. Based on our observations, we concluded the
contribution of the IL-5 to formation of the EETs that is different from neutrophils’ EETs.
This result was similar to the study with the donors with atopic dermatitis (Ueki et al,
2012).11 Thus, we showed the following morphological differences: (1) the holes on the
cell surfaces of eosinophils; (2) extracellular eosinophils’- derived granules; (3) decondensed nucleus that changed the “lobularity” to the single, and round shape; and (4)
protrusions of the plasma membrane (PM) with concentration of granules in a cytoplasmic
side. Furthermore, the staining of eosinophils with antibodies against F4/80 protein
expressed the immunofluorescence lighting that is close to the expression on RAW cells
and macrophages. This is comparable to the result with human derived cells was
demonstrated by Choi et al, 2018.12
The significance of the results showed the findings of EETs in vitro were
comparable with the findings of different researches in vivo. Moreover, the study in vitro
of the BM derived eosinophils of mouse that were grown 252 days was not described been
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previously in addition to the age-dependent morphology of such eosinophils, and IL-5
stimulated EETosis.
Our analyses suggest the long-term differentiation method of the eosinophils and
macrophages from BM cells of mouse in vitro, may be widely applicable in identifying
conditions that contribute to the developing of the pathogenic mechanisms in vivo. The
new appeared morphologies of eosinophils may be used to study the functions these types
of cells. The long-term of amplification of cytokines and developing the EETs could be
used in the study in toxic effects of eosinophil-derived granules and in protein compositions
of the nuclear DNA-derived histones which may change the histological structures and
functional properties of tissues. These changes could ultimately result in the formation of
various diseases, such as Well’s syndrome and Bullous Pemphigoid (Amber et al, 2018175).

4

LITERATURE REVIEW
1.

Development of Eosinophils
The first description of eosinophils was in 1879 by Paul Ehrlich who stained cells

with acidophilic dyes. Eosinophils are very mysterious cells of the immune system and
have unique properties that attract a lot of investigators. Traditionally, eosinophils attribute
to the end-stage cytotoxic effector cells.
Eosinophils develop in the bone marrow from pluripotent hematopoietic stem cells
(HSCs) that turn to the multi-potent progenitor (MPP), then to the common myeloid
progenitors (CMPs) followed by the eosinophils progenitor (EoPs) (James J. Lee et al.
2012).13 Human’s EoPs are determined through surface phenotype Lin-, IL-5Ra+, CD34+,
CD38+, IL-3Ra+, CD45RA- (Iwasaki H et al, 2005).14 Subsequently, Mori et al, 2009 had
argued that human granulocyte macrophage progenitors (GMPs) do not convert to
eosinophils. They appeared in the mature stage and exist in the peripheral blood half-life
of 18 hrs (Rosenberg et al, 2013).5 Eventually, eosinophils migrate to the gastrointestinal
tract (GIT) or thymus and abide under homeostatic state (Lamouse-Smith ES, Furuta GT,
2006).15
Transcription factors are essential to the differentiation of eosinophils. Those
factors are GATA-1, C/EBP-a. McNagny K, 2002. Ectopic expression of both transcription
factors (GATA-1 or C/EBP-a) is shown in cord blood progenitors to result in the
differentiation of eosinophils.16 Other transcription factors induce PU.1, FOG-1, and
GATA-2. Next, important unit for differentiation of
5

eosinophils are the cytokines that are IL-3, IL-5 and GM-CSF (Sanderson, 1992)17. These
have influence on differentiation and survival of eosinophils. The most important cytokine
is IL-5 which maintains proliferation of eosinophils from the bone marrow (Clutterbuck et
al, 1989).18 Eosinophils play an important role in the inflammation cycle. During
inflammation, EoPs increase their population, appear in blood circulation and within
inflamed tissue. Also, eosinophilopoiesis can occur at extramedullary site (Radinger M,
Lotvall J, 2009).19 Eosinophil-induced inflammation is a local peculiarity of development
of complications of asthma leading to the lung dysfunction (Choi et al, 2018).12 Thus,
evolutionary stabilization of eosinopoiesis in mammals attracts investigators to elucidate
the importance of immunological changes in mice models (Lee et al, 2012).13

2.

Evolutionary Conservation of Eosinophil-Dependent Genes
The influence on biological reactions attribute primarily to eosinophils-relative

cytoplasmic granules. There are primary, secondary, lipid bodies, and small granules
(Simon et al, 2017).20
Gleich et al, 19931, refer to eosinophil-associated genes to the group of genes that
encode the secondary granule proteins including: (1) eosinophil major basic proteins
(MBPs), (2) eosinophil associated ribonucleases (EARs), (3) eosinophil peroxidases
(EPXs), or (4) primarily cytoplasmic protein with Charcot-Leyden crystal (CLC) that was
detected in eosinophil-mediated inflamed tissue.21 Nether, the role of MBPs and CLC nor
necessity of degranulation and site-specific appearance of mentioned proteins are well
understood (Lee, 2005).22 Giusti et al, 2017, related eosinophil derived neurotoxin (EDN)
and eosinophil cationic protein (ECP) to the secondary granules also.23 These granules are
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extremely toxic to tumor cells, parasites and microbes (Long et al, 2016).24 For example,
Bystrom et al, 2011, in vitro experiments showed ribonuclease is capable of extirpating
parasites, bacteria and viruses.25 Moreover, Young et al, 1986, argued that “ECP forms
pores or transmembrane channels, which ultimately results in cellular damage and death”.26
Therefore, ECP is responsible for apoptosis of epithelial and neuronal tissues (Navarro et
al, 2010).27 Next, MBP also shows a toxic effect. Thus, MBP causes a changing of charge
of the cellular surface membrane. The consequences of this include changing permeability
and disruption and injury of cell (Simon et al, 2017).28
MBPs are orthologous gene pairs (MBP-1, -2) and exist in humans as well as in
mice (Barker et al, 1991).29 Macias et al, 2000, mentioned that “In both species, the
abundance of the protein encoded by MBP-1 is the highest on a molar basis among the
eosinophil secondary granule proteins and is greater than an order of magnitude higher
relative to the protein encoded by the MBP-2 gene”.30 Interestingly, human MBP-1 has
multiple promoters for transcription and is characteristically cationic (Li et al, 1995; Plager
et al, 1999).31-32 Human MBP-1 shows much more active expression in eosinophils,
however, it is also detected in other leukocytes (Ackerman et al, 1983).33 MBP-1 can also
be expressed by Placental X cells and elicits during the pregnancy as “Pro” – form (Wagner
et al, 1994).34
Secondary granules have the crystalloid core and include MBP and are shrouded
by ECP and EDN, which was attributed to the ribonucleases (Giusti et al, 2017).23 It is
known that ECP is refer to the marker in different inflammatory disorders (Di et al, 2012).35
EARs are genes that are attributed to many family members and stored in the
secondary granules as the ECP and EDN of the eosinophils (Rosenberg, 1989).36 EARs are
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the second most abundant ribonucleases. ECP is highly cationic with low ribonuclease
activity and present in humans and Old-World primates. EARs genes are expressed in
different cells (leukocytes), non-hematopoietic type of cells as well as in eosinophils
(Shapiro et al, 1991; Sur et al, 1998).37-38
EPX are genes that encode the proteins with high peroxidase enzymatic activities
(Horton et al, 1996)39 and are part of myeloperoxidase (MPO) and eosinophil peroxidase
(EPX). These genes are dedicated as most abundant (by weight) mature proteins of
secondary granules of eosinophils. The recent literature does not have any information
about appearance of EPX in other leucocytes as well as non-hematopoietic cells. Therefore,
EPX genes attribute to eosinophils as the eosinophil-specific property (Lee et al, 2012).13
CLC are lysophospholipase that expressed within the cytoplasm; however, the
primary granules of the eosinophils include these proteins (Weller et al, 1980).40
Conversely, Ackerman et al, 2000, argued that “Human CLC is not lysophospholipase and
instead is a member of the larger Galectin family that is also described as galectin-10”.41
Kubach et al, 2007, demonstrated the expression CLC/Gal-10 also found in T regulatory
cells. CLC/Gal-10 important because it is the gene that has the highest expression in
eosinophils (Nakajima et al, 2001). Currently, the role of CLC gene still is unclear and
needs future investigations.43

3.

Cytokines and Chemokines Production
Different types of inflammation such as tissue injury or infection elicit different

cytokines and stimulate the cells of specific tissue to synthesis adhesion molecules and
chemotactic factors. This cascade of signaling events recruits different leukocytes,
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including eosinophils. The inflammatory mediators andp1 cytokines represent to bias
hematopoiesis to activate the differentiation of granulocytes (Takizawa et al, 2012).44 Thus,
eosinophils express different cytokines that are activation and proliferation-induced ligand
(APRIL), IL-6, IL-4, IL-5, IL-13, IL-10 and TNF and contribute to the survival of plasma
cells (Chu et al, 2011; 2012).45-46 Spencer et al, 2009, demonstrated the expression of
different types of cytokines by eosinophils.47 Thus, Th1: IL-12 and IFN-y; Th2: IL-4, IL-5,
IL-9, IL-13, IL-25; pro-inflammatory cytokines: IL-6, IL-1b, TNF-a; suppressive: TGF-b,
IL-10, indolamine-2,3, oxygenase. Eosinophil IL-16 is an important cytokine in T-cell
recollection. Schollaert et al, 2014,57 argued that stimulation with CCL11 would result in
actin polymerization in cultured eosinophils as well as blood eosinophils. Schollaert et al,
2014, concluded that these “Findings indicate that the cultured eosinophils are functionally
competent with mild differences in response to mediator activation compared to peripheral
blood eosinophils”. Using cytokines for differentiating eosinophils from the BM cells were
not effective for producing a large quantity of mature eosinophils. Thus, BM progenitors
were cultured with IL-3 and GM-CSF that increased the quantity of cells with low (5-6%)
mature eosinophils (Ishihara et al, 2000).58 However, authors cultured the rat BM
progenitors with IL-5 and got 90% eosinophils, but with a decreasing total number in a 4fold. Dyer et al, 2009, showed the synthesis of the cytokines by mice BM eosinophils
(bmEos) 24 hours after treatment with IL-5 that are: IFN-y, IL-4, IL-6, MIP1a, IL-9 and
IP-10.4. Next, eosinophil-induced production of IL-4, IL-5, and IL-13 contributes to the
Th2 polarization (Spencer et al, 2009).47 In the culture of BM cells of mice, with
stimulation of SCF, FLT3L prior to IL-5, differentiated eosinophils secreted spontaneously
IL-4 and IL-6
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The eosinophils can stimulate T-cells and the Th2 environment. Moreover,
eosinophils express both a b cell-activating factor of the TNF family (BAFF) and APRIL
that have an influence on normal function of B cells as well as autoimmune B cell
stimulation (Dillon et al, 2006).48 Also, APRIL interacts with the transmembrane receptors,
calcium modulator ligand interactor (TACI) and B cell maturation antigen (BCMA)
(Gras et al, 1995).49 Next, APRIL is capable of activating B-cell antigen presentation,
encouraging antigen-activated B-cells, facilitating isotype switching in B cells, and
increasing preservation of the plasma cells (O’Connor et al, 2003).50 On the other hand,
BAFF interacts as a growth factor for the B cells and activates immunoglobulin production
(Moore et al, 1999).51 Schall, et al, 1990; Alam et al, 1993 declared that “CCL5 (RANTES)
is a chemoattractant for CD4+ memory T cells, monocytes, and eosinophils”.52-53 Bacon et
al, 1995, demonstrated in vitro that RANTES increases activity of T lymphocytes in an
antigen-dependent scenario.54 Moreover, RANTES activates eosinophils as well as the
expression of an adhesion molecule that contributes to migration through the endothelial
layer (Rot et al, 1992).55 Eosinophils let out RANTES and IL-16 where IL-16 appeared as
the activator of attraction of CD4+ T cells. Despite the low concentration, RANTES and
IL-16 activate the migration of T-lymphocytes. Therefore, eosinophils might increase the
immune reaction through CD4+ lymphocytes that were shown during different
inflammatory diseases (Lim et al, 1996).56 Next, eosinophil-induced production of IL-4,
IL-5, and IL-13 contributes to the Th2 polarization (Spencer et al, 2009).47 In the culture
of BM cells of mice, with stimulation of SCF, FLT3L prior to IL-5, differentiated
eosinophils secreted spontaneously IL-4 and IL-6.
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Figure 1: The influence of the eosinophils on the function of different leukocytes

T cell differentiation to Th2 can be regulated by eosinophil-dependent indoleamine
2,3-dioxygenase (IDO) that contributes the conversion tryptophan to kynurenines
(Odemuyiwaet al, 2004).59 In addition, it has better shown that eosinophils can act as Th2
adjuvants through regulation of Dendritic cells (O’Connell et al, 2011).60 Elevated blood
eosinophils exist during different types of inflammation. Thus, we need the better
understanding how are eosinophils related to the host’s inflammatory responses. Haldar et
al, 2009, demonstrated the role of IL-5 plays a critical function in disease – associated
eosinophilia61. Currently, the role of IL-5 for an induction of the eosinophil lineage-
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committed progenitor (EoP) into eosinophils still be under investigation. Although, it has
been shown that IL-5 targeted treatment can effectively decline the number of the mature
eosinophils as in the blood and in the bone marrow (BM), however, it cannot change the
number of EoPs. Schollaert et al, 2014, said that “a variety of cytokines and growth factors
combinations have been used to expand progenitor ex vivo, with stem cell factor (SCF)
and fms-like tyrosine kinase 3 ligand (FLT3L) demonstrate the positive effects on CD34+
progenitors”. However, the proportion that is necessary to effect change for mature
eosinophils is unknown. Previously studies demonstrated a “phenotypically mature
eosinophils” (Dyer et al, 2009). Dyer et al, 2013, expanded progenitors with stem cell
growth factor SCF and FLT3L followed by IL-5-mediated differentiation. This result
would correlate with study the “mature eosinophils”.4-5 Moreover, higher level of IL-5
could activate cell division in the periphery and increase differentiation of BM cells. Also,
the authors demonstrated the method to culture of eosinophils with fresh and frozen
stimulated BM cells in 96-well plates. Lately, Dyer et al, 2009, demonstrated the FLT-3
ligand functions as an element that activates the growth “primitive, highly proliferative
progenitors, and SCF supports the growth, especially, eosinophils’ progenitors.”4
IL-31 was attributed to the IL-6 family of cytokines through activation of Th2 cells.
Rudrich et al, 2018, showed that eosinophils are the primary source of the IL-31 in the
patients with Bullous Pemphigoid.66 Moreover, IL-31 activates endothelin-1 responsive
neurons and brain natriuretic peptide (BNP), that is important component of itching
(Takamori and Nambu, 2018).67 Feld et al, 2016, argued that IL-31 contributes to nerve
growth and branching.68
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Substance P is released from peripheral nerves and has a function as a vasodilator,
and interacts with eosinophils (Wallenger et al, 1986).69 Pavlovic et al, 2008, showed in
mouse models of atopic dermatitis that “Degranulated eosinophils have been found
surrounding an increased number of Substance P-positive nerve fibers in lesion skin”.70
Moreover, nasal irritation with Substance P in patients who had allergic rhinitis contributes
to an increased level of eosinophils (Fajac et al, 1995).71 Interestingly, Substance P inhibits
apoptosis in the same fashion as IL-3 and increases the survive of eosinophils; thus,
Substance P interfere in disease progression (Raap et al, 2015).72 In addition, Substance P
activates the nerve growth factor (NGF) and IL-31 from eosinophils, increases the neurons
sensitivity and itching (Friedman et al, 2015).73 Also, Substance P activates chemotaxis
eosinophil, activity, and survival. Mast cell-eosinophils crosstalk and provoke neuroimmune communication direction. The result of this communication reinforces substance
P itch.

4.

Eotaxins
The Eotaxins have different functions besides the activation of the Th2 polarization;

the key function of eotaxins is an attraction of the eosinophils to the target tissue. The
chemokines CCL11, CCL24, and CCL26 are related to eotaxins are expressed in response
to inflammation. (Gunther et al, 2011).74 Moreover, all eosinophils in peripheral circulation
express CCR3, that is the main eotaxin receptor (Liu et al, 2003).75 Increased levels of
eotaxin, IL-5, and CCR3 were found in the solution of blisters and inflamed skin as well
as an increased number of dermal eosinophils.76 Furthermore, activated eosinophils are
prominently associated with CCL11 and CCL26 and with inflammatory response.
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Interestingly, Schollaert et al, 2014, demonstrated the influence of the CCL11 (ligand for
CCR3) and the robust increase of mature eosinophils in cell culture of mice. They observed
that EoPs that are CCR3 deficient did not show the migration toward CCL11, however,
demonstrated the migration to the LTB4.57 Thus, Schollaert et al, concluded that “CCL11
stimulated chemotactic response was depended upon CCR3 and that the cultured
eosinophils migrated in an agonist-specific manner”. Jean-Baptiste et al, 2002, declared
that expression of eotaxin looks like a consistent sign of all eosinophil-associated
inflammatory disorders of the skin.65
Chemokines or chemotactic cytokines are important participants in conditions by
which the leukocytes move to the inflammation side (Kitaura et al, 1996; Ponath et al,
1996). Today exists two major families of chemokines that are based in sequence of
cysteine groups: CXC and CC subfamily; two minor families: CX3C and
C chemokines.62-63 Eotaxin and MCP-4 are chemokines that activate Th2 as well as
eosinophils. Thus, mRNA of both chemokines expressed in biopsies from inflamed tissues
as well as in eosinophils (Gounni et al, 2006).64 However, how eosinophils contribute as
the primary source of these chemokines is still questionable (Jean-Baptiste, 2002). 65

5.

Degranulation of Eosinophils
The effector function of eosinophils as granulocytes is the release of extracellular

granule contents. In particular activated eosinophils are capable of releasing of intact
granules and preformed granule content in response to stimuli. This function of eosinophils
is independent of Endoplasmic Reticulum - Golgi releasing pathway.
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The studies in vitro / in vivo demonstrated four degranulation pathways:
1) Classical endocytosis. The granules releasing by fusion with PM; 2) Compound
exocytosis. Multiple granules fused together before the fusion with the PM; 3) Piecemeal
degranulation (PMD). The secretory vesicles that include the granule contents are fused
with PM; and 4) Cytolytic release (ECL). During necrosis of eosinophils, intact
cytoplasmic granules release by rupture of PM (Lee et al, 2012).13 The most common
pathway of degranulation of eosinophils is PMD. This mechanism can occur in response
to certain environmentally relevant stimuli. Abu-Ghazaleh et al, 1989, argued that such
stimuli are “Antibody mediated crosstalk of Fc receptors”.77 Other studies of different
diseases demonstrated the release of the ECL as the human eosinophil-associated granule
component. These diseases included asthma (Erjefalt et al, 2000), rhinitis (Greiff et al,
1998), atopic dermatitis (Leiferman, 1998), acute lung injury (Willetts et al, 2011), and
eosinophilic esophagitis (Protheroe et al, 2011).78,79,80,81,82
The common function of eosinophil degranulation is cytotoxicity. Thus, ECP
contributes to pore generation resulting in damage of cells (Young et al, 200).83 MBP
activates degranulation of mast cells and basophils, and inhibits the action of muscarinic
M2 receptors of the Vagal nerve (Adamco et al, 1999).84 However, the role of effector
function of the eosinophils still is questionable and needs more experimental data (Lee JJ
and Lee NA, 2005).22

6.

Co-operation with Peripheral Nerves
Eosinophils reinforce the innervation of skin through shivered dorsal root ganglion

neurons,

thus,

contributing

to

growth
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and

branching

of

neuronal

tissue

(Foster et al, 2011).85 Also, eosinophils regulate realizing of neurotransmitters and defend
from apoptosis that can be induced by cytokines. The cause for this protection is expression
of neuronal NFkB through eosinophils adhesion to neural intercellular adhesion molecule-1
(ICAM-1) (Curran et al, 2004).86 Accordingly, interaction between eosinophils and
neuronal tissue was observed in human skin of patients with atopic dermatitis. High nerve
density was observed around eosinophil granule proteins. In mouse models was found that
IL-5 induced eosinophils were observed in the same epidermal region of increased
neuronal tissue. These In vitro observations with cultures of eosinophils have found an
increase in branching of neurons (Foster et al, 2011).85 Therefore, it is possible that
eosinophils activate the growth of neuronal tissue.

7.

Co-operation with the Autonomic Nervous System
Two pathways of collaboration exist between the eosinophils and autonomic

nervous system. The evidence of one of these pathways is shown the experiment in vitro
the eosinophils surround the cholinergic nerves to result the activation of NFkB and
activator protein (AP)-1 within neuronal tissue leading to nerve growth (Walsh et al,
2004).87 The other evidence is shown the experiment with guinea pigs demonstrating
eosinophils around parasympathetic neuron system (PNS) to lead to reactive oxygen
species (ROS) within the nerves, as well as activation of p38 MAP kinase (Kingham et al,
2003).88 Eosinophils also promote the remodeling of cholinergic neuronal tissue by
releasing eosinophilic derived granule proteins. Morgan et al, 2005, showed that signaling
pathways of the nerve cells were activated by eosinophil’s cationic proteins by
phosphorylation of the MAP kinases ERK ½, p38, and AKT following by induction of the
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nuclear transcription factor NFkB.89 Next, EPX upregulates choline acetyltransferase
(ChAT) and gene expression of vesicular acetylcholine transporter (VAChT); however,
MBP upregulates choline acetyltransferase VAChT alone. In summary, eosinophils initiate
the production of acetylcholine with the previously described cascade whereas ChAT
activates the production of acetylcholine, and VAChT controls packaging into vesicles for
action of synapses (Akashen et al, 2014).90
In addition to co-operation with autonomic nervous system, the experiments in vitro
showed that MBP and NGF have an influence on upregulating M2 receptor expression and
these changes represented a decrease of intracellular neural acetylcholine (Durcan et al,
2005).91 Moreover, MBP upregulates of adhesion-dependent activation of ERK1/2 and
protects the neuronal tissue from apoptosis through expression of gene bfl-1,2 that have
the anti-apoptotic properties (Morgan et al, 2004).92 Therefore, MBP that is released by
eosinophils during inflammation regulate nerve plasticity through anti-apoptotic action.

8.

Eosinophil Extracellular Traps (EETs)
The eosinophil extracellular trap (EET) includes network-like structures containing

DNA, nuclear proteins and granule proteins and was presented from early studies on
neutrophils. It was recognized that neutrophils can produce the extracellular DNA trap cell
death that is ETosis (von Kockritz-Blickwede et al, 2009).93 Neutrophils-mediated ETosis
developed over one or more hours that is different from apoptosis and necrosis (Brinkmann
et al, 2004).94 Unlike the apoptosis, ETosis does not produce the nuclear condensation and
DNA fragmentation. Fuchs et al, 2007, said that “Instead, nuclear chromatin decondenses
in the cytoplasm”.95 Consequently, nuclear DNA is released through the plasma membrane
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and develops an extracellular DNA trap. The function of those traps for the neutrophils is
to concentrate the free antimicrobial molecules that are histones and granule proteins.

Figure 2:The releasing of the intact granules through lysis of eosinophils during
eosinophil ETosis (EETosis)

Shingerau Ueki et al, 2013, observed eosinophils of patients with sinusitis and
hypereosinophilic syndrome and concluded that “reveled the liberation of free extracellular
granules as well as nuclear changes (disruption of nuclear membranes and decondensation
of nuclear chromatin) that were distinct from apoptosis and necrosis”.96 For example,
eosinophils that undergo to apoptosis display condensed compaction of chromatin and form
apoptopic bodies that are shrinking and budding a whole cell. The same authors argued
that realization of nuclear DNA or cell-free granules from the eosinophils do not occur
during apoptosis of eosinophils or necrosis. The experiments were carried out with
utilization of the different stimuli for cytolysis that include: IgG, IgA, PAF with IL-5 or
with GM-CSF, calcium ionophore. The results showed lytic death of the eosinophils
through induction of ROS. Ueki et al, 2013, demonstrated the eosinophils that were
activated by IL-5 and IFN-y and were released noncytolytically mitochondrial DNA and
formed extracellular DNA traps. However, Shigeharu Ueki et al, 2013, identified the
different ways by which eosinophil-associated nets with DNAs were formed. Thus, the
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authors concluded that similar to neutrophils, eosinophils-associated ETosis demonstrate
the cytolitic release of nuclear DNA and extracellular DNA nets. Moreover, Shigeharu et
al, 2013, showed that bi-lobed nuclei of eosinophils regenerated into one lobed nuclear
structure and granules of eosinophils release out of cells as structures that were enveloped
by the plasma membrane (PM). Afterwards, nuclei formed the DNA nets intracellularly
following the breakdown the PM of eosinophils and the liberation the nets of nuclear DNA
(histone-positive) and granules. Papayannopoulos et al, 2010, mentioned that ETosis of
neutrophils leads to association of granule-containing proteins to the nuclear DNA
following the rupture of the PM. Thus, bounded to DNA, intact granules of neutrophils
can’t be recognized.97 Unlike neutrophils, eosinophils released intact granules without
binding to the nuclear DNA during ETosis. Therefore, eosinophil granules proteins might
exist in both fashions: (1) within granules and (2) bound to DNA nets. The same study
demonstrated by enzyme-linked immunosorbent assay (ELISA) showed that stimulation
of eosinophils by eosinophil-active chemokine CCL11 elicited secretion ECP and granule
AO. However, CCL11 did not activate any secretion of other granules (PM-enveloped
granules). Thus, the secretion of PM enveloped granules requires a future study.
EETs have the function of the innate immunity to infectious diseases and activate
tissue damage within the bronco-pulmonary tract (Yousef et al,2008).98 Eosinophils
produce the EETs in a NADPH oxidase-dependent manner combined with ROS (Ueki et
al, 2013).96 EETs can increase up to in size to 15 times more than cells, thus, expanding
the specific targeting area (Cortjens et al, 2017).99 For example, EETs are found in the
biopsies of infectious diseases, allergic diseases, and autoimmune disorders. In these
discovers, around 10% of eosinophils release DNA; however, 30% of eosinophils release
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DNA during Well’s syndrome (Simon et al, 2011).7 The experiment ex vivo demonstrated
that within human skin separated eosinophils have shown that EET splits derma-epidermal
junction (DEJ), however, a prescription of DNase lowered DEJ separation. Despite modern
knowledge of EETs, the mechanism of contribution of EETs to separation of DEJ still is
unclear and needs more investigating. Choi et al, 2018, said that quantitative activation of
peripheral blood eosinophils promoted to the higher formation of the EET resulting in
increased inflammation in asthmatic patients. Thus, EET has unique biological properties,
however, where EETs activate the pathogenesis of asthma and other diseases is not known
(Choi et al, 2018).12 Thus, the function of the eosinophil-associated EET should be more
investigated.

9.

Link Between Eosinophils and Immunoglobulins
The link between eosinophils and IgE are FceRI receptors that have a high affinity

IgE receptor and have the low expression on eosinophils (Kinet et al, 1999).99 However,
FceRI has high expression on eosinophils during the inflammation within tissue
characterized by increased IgE and eosinophilia (Messingham et al, 2014).100 FceRI has
several chains where a-chain is regulated IgE binding and b- and y-chains participated in
signal transduction.

10.

Eosinophils are Antigen Presenting Cells
Previously, eosinophils were considered as effector cells, however, recent studies

have demonstrated that eosinophils have different functions that include: changes in the
tissue homeostasis, metabolism, and immune regulation in both diseases and physiological
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conditions (Xenakis et al, 2017).101 Thus, eosinophil can efficiently process antigens,
activate co-stimulatory molecules, move to the lymph nodes, and regulate T cell response
(Lucey et al, 1989; Lin, Lore et al, 2017).102-103 This function of eosinophils can be
stimulated by GM-CSF. For instance, wild-type mouse models showed that eosinophils
express surface markers MHC II and CD80 within lamina propria of the gastro intestinal
tract (GIT). However, Domachowske et al, 1998; Adamko et al, 1999 and Rosenberg et al,
2001, demonstrated that eosinophils are regulated by both innate and adaptive immune
responses through expression of the MHC-I and MHC-II, antiviral ribonucleases, cytokines
and chemokines, activating T cells.3,84,104 The experiment demonstrated that eosinophils
can be converted to APCs. The next study represented that eosinophils exhibited dendrites
that reached to prolonged distances. The experiment in vivo showed that mice were treated
with antigens and two distinct populations of eosinophils gained an intestinal antigen
(Xenakis et al, 2017).102 Additionally, the study of the patients with eosinophilic
esophagitis with using stain-immunohistochemistry, showed tissue eosinophils expressing
MHC-II and T-cell activation (Le-Carlson et al, 2013).106 In recent time the productivity
of eosinophils as APCs, their function in the skin and other tissues, and their ability to
process specific antigens still is unknown.

11.

The Receptors of Eosinophils
Eosinophils express intracellular and surface receptors that are important for the

cell’s functions. Eosinophil’s receptors sense the ligands and provide growth, adhesion,
chemotaxis, degranulation, and cell-to-cell interaction (Hogan et al, 2006; Blanchard and
Rosenberg, 2009).107,108 The interleukin-5 receptor (IL-5Ra), CC chemokine receptor 3
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(CCR3) and Siglec-8/Siglec-F are the most important receptors with unique functions.
Rose et al, 2010, said that within physiological conditions, existing among essential
markers that are not expressed on normal eosinophils (CD11, CD103, CXCR4, CCR5,
CCR6, CCR7, TLR2, TLR4, MD-2, RP105 and MD-1). Also, small account of cells
expressed CCR1 (27%) and CXCR3 (11%). Recently studies also showed 40 types of
different chemokines and five CXC chemokine receptors exists. The receptors include
eight CCR, one CX3CR, and one XCR (cloned) (Kitaura et al, 1996).62, 109 One of the
eosinophils’ receptor, CCR3, and it’s ligand CCR3. Eotaxin has influence on migration of
eosinophils. Moreover, Nagase et al, 2000, argued that low level CXCR4 and CCR3 were
expressed in recently isolated eosinophils from the patients’ blood. In contrast, cultured
eosinophils in vitro represented expression of CXCR4 (Chelucci et al, 1999).110
Interestingly, eosinophil’s CXCR4 expression is upregulated by IFN-y, whereas the same
cytokine downregulates the expression of CXCR4 in T cells. Eosinophil’s CXCR4
expression down regulated by IL-4 and the same interleukin up regulates those in T cells.
Lopez et al, 1986, demonstrated that CXCR4 is activator of apoptosis. 111 In contrast, IL3, IL-5, and GM-CSF protect the eosinophils from apoptosis and inhibit the CXCR4. A
definite level of IL-5 is required for inhibition of CXCR4 (Wallen et al, 1991).112 However,
IL-4 inhibits expression of CXCR4 and as such protects eosinophil against apoptosis. In
addition, Nagase et al, 2000, conclude that “In contrast to CCR3, the expression of which
is restricted only to eosinophils and basophils, CXCR4 is expressed in various white blood
cells (WBC), indicating that CXCR4-mediated migration is not the primary mechanism of
the selective accumulation of eosinophils observed in allergic inflammation. In addition,
mRNA was expressed in vivo with antigen application, and in vitro with treatment with a
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specific cytokine (Mochizuki et al, 1998).113 In conclusion of the study, eosinophil’s
expressed CXCR4 that upregulated by IFN-y and downregulated by IL-4, in conjunction
with IL-5, demonstrating the prevalence of the Th1 response rather than a Th2 response
following by CXCR4 expression.
Wooley (personal communication) demonstrated utilization of the unique cell line
that differentiates spontaneously in vitro study as eosinophilic myelocytes without
cytokines treatment. Thus, the mentioned cell line firstly was infected with T cell-tropic
(T-tropic) and macrophage-tropic (M-tropic) strains of human immunodeficiency virus 1
(HIV-1). Moreover, the author showed the expression of the HIV-1 receptor CD4 as well
as secondary receptors CXCR4 that used T-tropic strain and CCR5 that used M-tropic
strain (CCR3 was nor expressed). Thus, the current study demonstrated the expression of
co-receptor CXCR4 by the eosinophilic cell line that was utilized by the T-tropic strain for
a productive infection. Many authors use different cell surface markers in their researches.
Thus, Lee et al, 2012 said that “In both human and mouse, eosinophils may be described
simply as side-scatter cells staining positive for IL-5Ra and negative for the lineage
markers CD4, CD8, B220, and CD19”. Moreover, many different markers were used
during identification of eosinophils that are: CCR3 (human/mouse), Siglec-8
(human)/Siglec-F (mouse), EMR1(human), F4/80(mouse eosinophils and macrophages),
and CD11b (human/mouse).
The F4/80 is glycoprotein that was discovered 30 years ago as the antigen for the
F4/80 mouse antibody (Ab). Also, F4/80 is specific cell-surface Ag and marker for the
mouse macrophages/monocytes. The physiological conditions have influence for
expression of F4/80 on the surface of macrophages (Lin et al, 2005).104 McGarry &
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Steward, 1991, said that “Murine eosinophils are known to stain with F4/80 and even
Mac-1, but at lower intensity than is typical for macrophages and monocytes”.114 Some cell
surface markers could be sign of eosinophil activation. In fact, in both humans and mice,
eosinophils can activate their expression of CD69 in response to the activator which is
PAF. Also, both species up-regulate chemokine receptors (CX3CR1), co-stimulatory as
well as antigen presenting molecules (CD86 and MHC II). According to Wolley (personal
communication), who demonstrated the entry of X4 and R5 strains HIV-1 to eosinophils’
cell line that expressed CCR3 and all major co-receptors, and resulted in productively
infected eosinophils by X4 strain. Thus, the new cell line, which expressed CCR3 behaved
similarly to the parental line (Wooley et al, 2000) and imitated the productive infection,
with similar quantities of p24 protein, decreased the viability of eosinophil cell line during
increasing of viral production. However, the X4 strain of HIV-1 entered to the eosinophils
through CXCR4 co-receptor, and was shown to block such receptors by antagonist for
CXCR4. Thus, authors showed an eosinophilic cell line that expressed all necessary
receptors which was used by HIV-1. Thus, Wooley, said that “CCR5 for entry is that the
cells may not express appropriate amounts of this co-receptor on cell surface”. Thus, it was
shown that HIV-1 used receptors/co-receptors of eosinophils play an important role for
productive viral infection such cells.
Next important receptors for eosinophils are pattern-recognition receptors (PRRs).
IL-5Ra. The most essential impact for eosinophils’ function includes IL-5 which
is important cytokine Th2 immune response. Thus, IL-5 is activated by lymphocytes Th2
as well as by mast cells, normal killer NK and NKT cells, despite eosinophils themselves.
Moreover, the mouse models show different sources for IL-5 that are: c-kit+ innate natural

24

helper cells, and IL-25/IL-33 responsive innate cells (Moro et al, 2010; Neil et al, 2010).115116

The cytokines, IL-4 and IL-13, chemoattractants for eosinophils, eotaxins 1,2, and 3,

are synergists for IL-5, activate eosinophils, and recruit into tissue during acute
inflammation (Foster et al, 2001; Pease and Williams, 2001). 118,119

Figure 3: The receptors of eosinophils
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IL-5Ra is expressed by eosinophils and basophils in both humans and mice
(Takatsu et al, 2009).120 However, B1 cells of mice also express the receptors that have the
functions for proliferation and survival. The receptor of IL-5 is heterodimeric that has a
chain and interacts with a b subunit for the signaling pathway. In addition, the signaling
through b subunit interacts with the receptor for GM-CSF and IL-3. IL-5Ra senses the
ligand to result the in development of eosinophils from their progenitors, activation, and
survival functions. Kumar et al, 2008, said that “have considered possibility of eliminating
eosinophils directly, via targeting the IL-5Ra and the IL-3/IL-5/GM-CSF common beta
chain (Bc) or by inducing apoptosis via ligation of eosinophil-specific cell surface
targets”121 (Nair et al, 2009; Haldar et al, 2009; Castro et al, 2011; Pavord et al, 2012;
Molfino et al, 2012 said that “Humanized monoclonal antibodies directed against IL-5
(mepolizumab, reslizumab) and the unique subunits of its receptor, IL-5Ra (benralizumab),
are under exploration for the therapeutic management of dysregulated eosinophils”. Thus,
IL-5Ra that is the most important receptor for eosinophils, represents great interest for
investigators. 122,123,124
Chemokine receptors. One of the most prominent chemokine receptors of
eosinophils is CCR3 with function for mediation of eosinophil chemotaxis in response to
the eotaxins CCL1, CCL24, and CCL26 (Lloyd and Rankin, 2003).125 Moreover, CCL5
(RANTES), CCL8 (MCP-2), CCL7 (MCP-3), and CCL12 (MCP-5) activate the CCR3
receptor also. The next receptor for eosinophils is CCR1 that is the main receptor for CCL3
macrophage inflammatory protein (MIP-1a) and CCL5, as well as the platelet activating
factor receptor (PAF-R).
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Siglec-8 and Siglec-F. Siglec-8 is lectin that is a cell surface immunoglobulin-like
receptor that is expressed on eosinophils of humans, however, Siglec-F is a paralog that is
expressed on mice’s eosinophils (Bocher, 2009).126 Both receptors are members of the
large family of the carbohydrate-binding proteins that are structurally related. However,
Kiwamoto et al, 2012, showed the antibodies against Siglec-8 or carbohydrate ligand,
6’sulfo sLex, activate the apoptosis of eosinophils in vivo. 127 Thus, Siglec-8 represents an
important target for pharmacological integrations (Hudson et al, 2009).128
PRRs. Eosinophils express different families of PRRs (Kvarnhammar and Cardell,
2012).129 Toll-like receptors (TLRs) are less expressed within eosinophils than neutrophils
and macrophages. The study showed that eosinophils expressed TLR-1, TLR-4, TLR 7,
TLR-9 and TLR-10 and they have an influence for coordination of innate and acquired
immune responses T and B lymphocytes) (Nagase et al, 2003).130 It has been shown that
viral nucleic acids are double-strained RNA (dsRNA), single-strained RNA (ssRNA), and
dsDNA are recognized by eosinophils through activation of TLR-3, TLR-7, and TLR-9,
respectively. The results of such interactions are the release of IFNs type I and the initiation
of the eosinophil-mediated immune response (Alexopolou et al, 2001; Diebold et al, 2004;
Heil et al, 2004).131, 132, 133 Diebold et al, 2004 argued that “Although TLR-3 and TLR-7
both recognize viral DNA, TLR-3 uses toll-interleukin receptor domain-containing
adaptor-inducing IFN (TRIF) and does not require MyD88, while TLR-7 signaling is
MyD88 dependent”. Moreover, eosinophil’s TLR-7 sensed the synthetic ligand R-848 and
generated ROS that suggests the interaction of PRRs with viruses and activating the host’s
defense (Lund et al, 2004).134 Phipps et al, 2007, argued that surface and intracellular TLRs
interacted with antiviral immune responses, connected functionally to TLR ligands, and
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were expressed by eosinophils.10 Addition experiments with hypereosinophilic (IL-5 Tg)
mice or by adoptive transfer of MyD88-sufficient mice that were infected by RSV resulted
in the effective clearance of virus by eosinophils via the MyD88 pathway. However, with
transfection of the MyD88-deficient eosinophils to the WT mice that were infected by
RSV, the viral infection was not cleared sufficiently. In addition, hypereosinophilic mice
demonstrated inhibition of virus-induced complications, including airways hyperreactivity
(AHR). The next experiments by the same group of authors demonstrated that TLR-7’s
ligand, ssRNA, induces eosinophils functions that are degranulated and shown the
activation of expression of the phagocytic receptor CD11b. However, Hemmi et al, 2003,
showed that when used, the MyD88-deficient eosinophils the reduction of the ssRNAinduced CD11b expression was not efficiently observed.135 The ssRNA could be sensed by
different cytosolic receptors within eosinophils, however, this requires additional study.
Also, the inhibition of RSV-associated infection mediated by eosinophils and the inhibition
of lung function depend on the MyD88 pathway as well as the production of NO by NOS2. Next, Phipps et al, 2007, study showed in vivo the expression of both mEAR-1 and
mEAR-2 by eosinophils within 24 hours of RSVs, which suggested that mEARs expression
was dependent on the TLR pathway. Thus, the authors demonstrated the activation of
innate antiviral immunity by eosinophils in response to RSVs-TLR-My-D88 dependent
fashion.
Eosinophils and viruses. It was previously shown, that the response of eosinophils
to the HIV-1 infection and the ability of X4 strain to infect productively of eosinophilic
cells using CXCR4 co-receptors for the viral entry (Wooley by personal communication).
Hypereosinophilia is common finding in late stage during AIDS (Wooley; Skiest and
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Keiser, 1997).136 Manetti et al, 1994, argued that the high level of CD8+CD30+ T cell
clone activates the Th2 cytokines, especially, IL-5, which was found in the infected by HIV
donors.137 However, another author did not find such response. Later, Phipps et al, 2007,
demonstrated eosinophils’ reaction toward RSVs and activation of TLR-7-MyD88
pathway which provided effective clearance of viruses and host’s defense mechanism as
well as inhibition of AHS syndrome10. Moreover, Dyer et al, 2007, represented the results
of recruitment of eosinophils to the lung during RSV and pneumonia virus of mice (PVM)
that can infect eosinophils (human and mouse respectively).138 Thus, the group of authors
represented “a double-edged sword” that means the consideration the two ways of behavior
of eosinophils: the antiviral response and the promotion of viral infection. Supporting the
first way of eosinophil’s function during viral infection was shown that eosinophils and
their granules decline the viral infection of RSV in the epithelial cell culture (O’Byme et
al, 2001).139 Furthermore, Adamko et al, 1999, argued about the inhibition by eosinophils
of titers of Sendai virus (parainfluenza virus 1) in quinea pigs. In contrast, the second way
of the eosinophil-mediated function is the contribution to PVM infection and “serving as
target cells supporting pneumovirus replication” (Dyer et al, 2007).

138,140

The authors

showed that RSV as well as PVM contributed to productive viral infection in human and
mouse eosinophils. During the early stages of RSV infected humans’ eosinophils, their
uptake by human were observed the virions in cytoplasmic vesicles of eosinophils two
hours after the viral attack. However, authors did not demonstrate the productive
replication (Kimpen et al, 1996).141 Later, Kolokoltsov et al, 2007, demonstrated the
earliest step of RSV infection with the development of endosome using pH-independent
uptake of epithelial cells of human.142 Similarly, Lei et al, 2008, investigated “IL-5 receptor

29

internalization by clathrin-coated endocytic vesicles, thus documenting the existence and
functionality of this mechanism in this lineage”.143 The localization of TLRs, especially
TLR-7, were shown in such regions, and were examined on eosinophils that activated the
transduction of PVM signals.
Rudd et al, 2005 and Liu et al, 2007, demonstrated on the mouse models of
eosinophils the release IP-10 (CXCL10) during viral replication.

144, 145

IP-10 is a

chemoattractant that is expressed by neutrophils and activates the movement of monocytes,
T cells, and natural killer (NK). Also, IP-10 is expressed by epithelial cells of mice that
were infected by RSV (Culley et al, 2006; Haeberie et al, 2001).146,14 Dyer et al, 2009,
firstly documented that bmEos released IP-10/CXCL10 from “preformed stores” in both
wild-type (WT) mice as well as MyD88-/- mice in response to PVM infection.4 Moreover,
the authors found that IL-6 release in response to PVM in mouse models also. Thus, was
shown that IL-6 inhibits the viral replication in MyD88-/- and activates the replication in
WT animals. This is supported by Dyer at all, 2009, that “suggesting the existence of a
MyD88-dependent IL-6-mediated feedback mechanism”. By investigating the RSV, the
authors presented human eosinophils that were infected by RSV resulted in “replicationdependent release of IL-6, a cytokine localized to specific granules and released in response
to mast cell chymase, IL-23, and various TLR ligands”. Moreover, the authors argued that
eosinophils support productive viral replication, targets for viruses, release the virions and
that IL-6 inhibits the “responses in themselves and probably in other infected cells”. In
addition, Dyer et al, 2007, said that the function of eosinophils is not discovered
completely, and some principles that investigators do not understand.138 Those principles
characterize of eosinophil’s contribution to clearance viruses within a lung tissue in vivo
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and to develop antiviral function in vitro, albeit, in different circumstances. This shows the
contribution to the developing severe viral pathology within the lung’s tissue by the
recruitment to such tissues of eosinophils.

12.

Regulation of the Immune Microenvironment by Eosinophils
The essential function of eosinophils was demonstrated during the adaptive

immune response when isolated from patients. Akuthota et al, 2010, found high levels of
MHC II and co-stimulatory receptors expression on humans’ eosinophils.148
Jacobsen et al, 2011, in experiment in vivo, used eosinophil-deficient mice, and
“eosinophils were demonstrated to modulate directly the local immune polarization of Th2
versus Th1/Th17T cell responses”.

149

This experiment could not be used on human’s,

however, the same correlation was found between eosinophils and polarization of immune
cells in many pathological disorders (Percopo et al, 2009). 150 Moreover, the experiments
with mouse models showed the function of eosinophils in plasma B cell survival that was
dependent on IL-6 and APRIL (Chu et al, 2011).
models in research of homeostasis of glucose.
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Wu et al, 2011, also used mouse

Authors determined that macrophages

can be regulated by eosinophils within an adipose tissue. Chawla et al, 2011, said that
“these immune regulatory activities of eosinophils on macrophages in mice may represent
a novel inflammatory process linked with metabolic diseases of humans where
inflammatory macrophages are known to be significant mediators of diseases”.

153

Furthermore, mouse eosinophils represented the modulation of immune environments for
recovery on physiological functions which are the evolution of reproductive tissues and
neuronal tissues (Timmons et al, 2009). 154 Kim et al, 2010, argued about localization of
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eosinophils in thymus that could develop the function that has influenced the negative
selection of T cells. 155 In addition, Kvathammar and Cardell, 2012, mentioned anti-viral
effect of eosinophils which was associated with activation TLRs and presence of viruses.156

13.

Eosinophils and Other Disorders
Eosinophils rouse in the bone marrow (BM) from CD34+ - committed progenitors,

and are found in high level in the BM during different diseases. Accordingly, these are
referred as disease-associated eosinophilia (Schollaert et al, 2014).57 Corrently, a little
information is known about development and the recruitment of eosinophils (Rosenberg et
al, 2012).5 Moreover, there is a lot of misunderstanding about the function of eosinophils
in eosinophil-associated diseases. Schollaert et al, 2014, said that “The pathways central to
the biology of the eosinophils lineage committed progenitor remain largely unknown”.
Thus, the regulation of the eosinophil’s lineage –committed progenitor differentiation an
emerging field for investigation and possible with future therapeutic targets. In asthma,
eosinophils are activated the pathogenic mechanism of this diseases. Different types of
viruses which are cause asthmatic disorders, include: Influenza virus, Parainfluenza, RSV,
Coronaviruses, and Rhinoviruses. Thus, eosinophil-associated and virus-associated
interaction attract a lot of investigators because do not exist well-grounded knowledge
about such mechanism. One example of this is Bullous pemphigoid (BP) (Crotty et al,
1983; Nishioka et al, 1984).157
Eosinophils and helminthes. Rosenberg et al, 2013, discussed the possibility of
providing immunity by eosinophils toward helminths, however, the studies on the animals
showed that eosinophils promote the duration of some of parasite.5 The authors showed
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that eosinophils functioned immunomodulatory cells, and eosinophil-deficient mice, T.
spiralis did not show survival function due to the decreased Th2 immune response. Thus,
the authors concluded that helminthes could replenish eosinophils to promote active
survival function, however, it could be balance between Th2 and Th1 toward
Th1-dependent oxidative burst. Thus, the function of eosinophils toward parasites remains
unclear.
Eosinophilic esophagitis. Landres pointed details about eosinophilic esophagitis
(EE) in 1978. Thus, the main cause for eosinophilic esophagitis is by dysregulated
hypereosinophilia, which depended on Th2 type immune response.5 Also, such patients
suffered from allergies to food, and dust. The biopsy samples showed activated eosinophils
with high level of granules (MBP) that showed increased level despite on remission
(Zhang et al, 2007; Blanchard et al, 2006).158,159 Also, the patients’ tissue demonstrated
highly activated Eotaxin-3 through unknown mechanisms. The EE still be under
investigation, especially, on the mouse models.
Bullous pemphigoid is an autoimmune disorder that characterized by blisters
resulting in high mortality and morbidity. Previously, the main pathological mechanism of
BP was IgG to BP-180 and BP230 where BP180 is type XVII collagen with main epitope
NC16A to which was shown high level of IgG (van Beek et al, 2016; Bagci et al, 2017;
Liu et al, 2017; Schmidt et al, 2000).

160,161,162,163

The authors declared that despite of

presented aetiologic aspect for BP and the character of anti-BP 180 IgG autoantibody, a lot
of clinical development and pathways are not understood (Amber et al, 2007). 164 Thus, the
authors argued that could exist different aetiologic properties for development of BP that
are “effector cells for cell-mediated immunity must be considered as significant
contributors to the pathogenesis of BP”. As was said before, the main sign of BP are
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urticarial lesions that have the fashion of the spongiosis and high level of eosinophils
between epidermis and derma which represent the dermo-epidermal junction (DEJ) as well
as presence of eosinophils in BP serum.

Figure 4: The dermo-epidermal junction
Moreover, the authors argued that metalloprotease-9 was secreted by eosinophils
inside of blisters and degranulation proteins of eosinophils were found at the side of
basement membrane (BM) and serum. Additionally, within BM extracellular DNA traps,
eosinophil-activated IL-5 separated DEJ, and eosinophil-mediated IgE against BP180
resulted in developing blisters. Further, during relapses of BP the following inflammatory
cytokines: IL-6, TNF-alpha, IL-8 as well as anti-inflammatory cytokines (IL-4, IL-10)
(Salz et al, 2017).165 In addition, Gounni et al, 2006, said that “An initial Th0/Th2-like
response would be seen in early stage of BP with IL-4, IL-5, and low levels of IFN-y.
Whereas in chronic phases, a Th1 response would follow with significant expression of
IFN-y” (Giomi et al, 2002).64

,166

Also, Frezzolini et al, 2002, mentioned about the

contribution of development chemokines during disease.167 Nakashima et al, 2007, pointed
out that during acute BP high levels of MCP-1, IP-10, and monokine induced by IFN-y
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(MIG) were present that signaled Th1 immune response.168 Gounni et al, 2006, discovered
that eotaxin and MCP-4 were present in eosinophil granules in the blisters in patients with
BP.64 Thus, the additional properties of eosinophils require future investigating, especially,
the role of eosinophils during BP as well as with viral-associated infection.

14.

Eosinophils: Human versus Mouse
Eosinophils from human and mouse have a lot of similarities that provide unique

possibility for research opportunities and approaches variety results in the treatment of
different diseases (Lee et al, 2012). The rodent models are most popular, when compared
with other animals, assist in the understanding about pathogenic mechanism of developing
human diseases.13
Hematologic origin, maturation. HSCs is commencement of terminally
differentiated eosinophils for both human and mouse. HSCs develop to MPP following to
CMP in both human and mouse. Unlike in the mouse, human’s CMP is branching to the
EoP, however, mouse’s CMP is developing to the Granulocyte Macrophage Progenitor
(GMP) and into EoP (Iwasaki et al, 2005; Mori et al, 2009). 14,169 Thus, Mori et al, related
the population of human’s CMP as IL-5Ra+ (EoPs). In contrast, human GMP do not
differentiate to eosinophils. Sanderson 1992; Clutterbuck et al, 1989; and Dyer et al, 2008,
demonstrated that IL-3, IL-5, and GM-CSF are important for survival, expansion, and
differentiation of eosinophils. However, IL-5 is the most prominent for eosinophil
development in both species and has influence for differentiation from BM cells.17,18,170
Morphology. In early beginning of 20th century, dyes for painting tissues and
writing solutions were used for staining of the blood cells. Thus, both human’s and mouse’s
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blood cells were stained with the dyes and cytoplasmic granules were stained with acidic
dyes. Also, the granules of blood cells are leukocytes, were named as “eosinophils”.
Moreover, Romanowsky was the first investigator who “mix the acidic aniline dye eosin
Y with azure B for staining of the blood cells”; and Giemsa (1902) and Wright (1902) were
renovated the delution of the eosin “Y: azure B or azure A+B (a.k.a. azure I) mixture”
(Romanovsky, 1891; Giemsa, 1902; Wright, 1902).13
Staining of eosinophils. Romanovsky-stained eosinophils of human are little
different from mouse that were examined by light microscopy. Thus, in both species under
the physiologic condition, the range of eosinophils are 1-3% of the total white blood cells
(WBCs). However, the human eosinophils are bigger in size 12-15 mm vs 9-12 mm,
respectively. Also, human’s granules are bigger in diameter as well as have higher number
in cytoplasm. According to Lee et al, 2012, that “Human eosinophils also stain a more
vibrant magenta with eosin relative to mouse eosinophils owing to the collectively higher
cationic change of the human granule proteins”. In both species the nuclei have a
polymorphism. The authors mentioned that nuclei in EoP transformed during development
from “spherical structure to elongated”. Thus, the nuclei transition is “mature
metamyelocytes segment into multiple lobes” in human eosinophils. In contrast, the
development of mouse’s from EoP to eosinophils that have nuclear “ring-like structure”.
Moreover, in contrast, mouse’s eosinophils have less heterochromatic fashion, compare
with the human’s eosinophils.
Electron microscopy. Dvorak et al, 1994; Egesten et al, 1986; Denzler et al, 2000
argued that the one of the most prominent difference between human and mouse
eosinophils is “unique appearance of the polymorphonuclear changes that often appear as
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multiple nuclear compartments within the cytoplasm reflective of the multi lobed (human)
or ring-like structure (mouse) of the nucleus traversing in and out of the section’s plane”.
Moreover, the same group of authors mentioned that exist “electron-dense crystalline core
within the secondary granules” that were found in both species and primarily consist with
MBP-1.171, 172, 173
Cell surface expression. One similar trait of the both species of eosinophils is the
high granularity fashion that important for the flow cytometric plots (side scatterhi). So,
both species can have the identification with a good quality. For instance, human as well
as mouse eosinophils have a “positive staining for IL-5Ra, and negative for the CD4, CD8,
B220, and CD19” (Wen et al, 2012).174 Moreover, it was mentioned before about markers
for eosinophils, however, the specific marker for the eosinophils of mice is CCR3. Also,
F4/80 express on the mouse eosinophils as well as on macrophages, however, EMR1 is
very specific for human. McGarry et al, 1991, said that “Murine eosinophils are known to
stain with F4/80 and even Mac-1, but at lower intensity than is typical for macrophages
and monocytes”. In comparison, both species express CD69 after an activation of PAF,
and will express the chemokine receptor CXCR1, with antigen presentation molecules
CD86 and MHC II.
Profound Differences. Some functions of human eosinophils are different, when
compared to mouse eosinophils. Thus, Rosenberg et al, 2007, mentioned that those
differences are: “Distinct responses to chemotactic cytokines, differential expression of
IgE receptors and siliac acid binding lectins, and highly divergent specific granule
proteins”. It is also observed different intracellular cytokine substance.10
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In addition, it was demonstrated that human and mouse eosinophils are very similar;
however, morphological, chemical, molecular difference, exist between these species.
Also, a many of the differences are unknown and require future investigating.
According to the National Academies of Sciences, 2018, that said “We owe our
good health to past investigators and the animals they studied”.
The current study focuses on the sophisticated function of eosinophils which
depended on morphology, environment, and time. Long-term culture of eosinophils may
change their phenotype, behavior, and functional characteristic. The growth factors (SCF,
FLT3L), and cytokines (IL-5, GM-CSF) can activate the differentiation of eosinophils from
bone marrow calls, increase their expansion, maturation, and survival. IL-5 downregulates
the CXCR4 that is activator of apoptosis, which allows to survive of eosinophils. Thus, this
study demonstrated the moderate level of survival eosinophils that were differentiated from
the BM cells in vitro, new morphological appearance of eosinophils, and developing the
EETs without viral infection that could be helpful for better understanding of eosinophil’s
biology. Many autoimmune disorders, viral infections can demonstrate high levels of
eosinophilia which might support pathogenesis of diseases, productive viral infection, and
release virions. Therefore, a new observation of long-term culturing of the bone marrowderived eosinophils with an application of the growth factors and cytokines in vitro will
enhance the clarification the pathogenesis of autoimmune disorders and inflammatory
processes.
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HYPOTHESIS
The hypothesis of this study is that long term culture of mouse bone marrow cells will
differentiate to the eosinophils and macrophages with the use SCF, FLT3L, IL-5 and GMCSF to influence the new appearance of eosinophils, protection from apoptosis by longterm of amplification of IL-5, and development of ETosis-like cytolysis in vitro. Newly
emerged eosinophil’s phenotype may explain the unknown functional properties of
eosinophils in vivo, and may contribute to understanding developing diseases. Long term
amplification of IL-5 will protect the eosinophil lineage from apoptosis and demonstrate
the independent development pathway of eosinophils for granulocytes. If this hypothesis
is shown to be correct, the differentiation of eosinophils from bone marrow cells can be
provided longer term to obtain the bi-lobular nucleus, dendrite-like shape of cell, and
development extracellular nuclear DNA-derived nets and free eosinophil granules.
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MATERIALS AND METHODS
1.

Materials

1.1

Animals
Pathogen-free, wild-type BALB mice, male and female, twelve-weeks-old, were

used obtaining the bone marrow cells. Mice were maintained in animal housing conditions
and were euthanized via carbon dioxide inhalation. The methods were approved by
protocols the Institutional Animal Care and Use Committee.

1.2

Chemicals/Reagents

- RPMI-1640 medium (Life Technologies)
- IMDM with Glutamax-1 (Life Technologies, Invitroment TM, catalog number:
31980-097)
- HBSS (Sigma, USA)
- Fetal Bovine Serum (FBS) (Atlanta Biologicals, catalog number: S11150)
- Penicillin-Streptomycin (Life Technoloqies, Invitrogen TM, catalog number: 15140-122
- Ethanol (Sigma, USA)
- Trypan blue (Sigma USA)
- Recombinant Mouse Granulocyte-macrophage Colony Stimulating Factor (rmGM-CSF),
1000 ng/ml (Pepro Tech, catalog number: 315-03)
- Recombinant Mouse IL-5 (R & D systems, catalog number: 405-ML-005)
- Recombinant Murine Stem Cell Factor (Pepro Tech, catalog number: 250-03)
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- Recombinant Murine Flt3 Ligand (Pepro Tech, catalog number: 250-31L)
- PBS (Life Technologies, Invitrogen TM, catalog number: 14200-166)
- Diff-Quick Stain Kit (Thermo Fisher Scientific, catalog numbers: 23-122-929,
23-122-952, and 23-122-937)
- DMSO (Mersk, India)
- Disposable syringe (1ml Insulin) 29G X ½ (Dispovan, U-40)
- Kleenex tissues
- 6 well plate
- Petridish
- Pipette tips
- 15 ml and 50 ml centrifuge tubes

1.3

Equipments
-

Dissection tools – scissors, scalpels, and packer

-

Centrifuge

-

370 C, 5% CO2 cell culture incubator

-

Microscope 0,3 A Nikon, JAPAN

-

Microscope OLYMPUS, BH-2

-

Hemocytometer
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2.

Methods

2.1

Stepwise Procedure for Isolation of Murine Bone Marrow Cells

Isolation of Bone Marrow – Day 0
The bones were removed from 20 extremities of mice (femur and tibia), using
sterile scalpel, scissor and packer, and the tissues were cleaned from the bones. Additional
ligaments on the bones remove by Kleenex, and thereafter were soaked the bones in 70%
ethanol for 2 minutes. Thus, bones were dipped to the sterile petri dish (100 mm x 15 mm)
with HBSS and the ethanol was rinsed off. Next, sterile petri dishes were used to place the
bones in culture medium (RPMI-1640) for 2 minutes. The interior marrow content was
exposed by cutting the bone’s caput femurs and tibia’s joins bodies. The marrow was
flushed with 2 ml of HBSS using with a 1 ml insulin syringe, and blown out into 50-ml
centrifuge tube. The needle of syringe was inserted inside of the bone space, marrow was
flushed, and collected in 50 ml centrifuge tube.

Bone Marrow Cell Suspension, Day 0. The bone marrow cell suspension was diluted by
HBSS for a final volume – 20 ml. Any clusters were removed by pipetting. The cells were
centrifuged at 250 g x 8 min. The supernatant was removed, and cell pellet was resuspended in 20 ml of HBSS. The cell suspension was centrifuged at 250 g x 8 min (wash
1). Then, the cell pellet was washed with 20 ml HBSS (wash 2). After 2 washes, resuspended the cell pellet from each femur/tibia in 20 ml of HBSS and made into a
homogenus suspension. The aliquot was removed, and cells count was determined. The
total number of cells was counted using the trypan blue staining and hemocytometer for
the cell viability. The cell suspension was centrifuged at 250 g x 8 min. According to the
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cell count that was obtained, the cell pellet was re-suspended in culture medium (RPMI1640 +10% FBS + 20 mM penicillin/streptomycin,100 ng/ml SCF, 100ng/ml FLT3L) or
(IMDM with Glutamax, 10%FBS, 100U/ml penicillin, 100mg/ml streptomycin, 100ng/ml
SCF, 100ng/ml FLT3L) to achieve a final cell density of 10 x 106 cells/ml.

Seeding of cells (Day 0) The 9.6 ml of culture medium was added into sterile 100-mm
petri dish; 3.0 ml of culture medium was added into sterile 6-well plate. The 0.2 ml of cell
suspension was added to each 100mm petri dish to achieve the final density 2 x 106
cells/petri dish; and final density of 6-well plate (3 x 106). 0.2 µl of rmGM-CSF was added
from GM-CSF stocks (1000 ng/ml) into above 100 mm petri dishes, the final concentration
in 10 ml is 20 ng/ml. The petri dishes were swirled gently and cells were incubated at 370C,
5% CO2 and 95% humidity for 3 days. 6-well plates: the cells were re-suspended in media
(IMDM with Glutamax, 10%FBS, 100U/ml penicillin, 100mg/ml streptomycin, 100ng/ml
SCF, 100ng/ml FLT3L) at of concentration 1 x 106 ml, plated at 3 x 106 cells per well in 6
well plates (3ml). The 6-well plates were swirled gently and cells were incubated at 370C,
5% CO2 and 95% humidity for 2 days.

Day 2. From 6-well plates, a 1.5 ml of cell’s growth was aspirated from each plate and
added the fresh media (IMDM with Glutamax, 10%FBS, 100U/ml penicillin, 100mg/ml
streptomycin, 100ng/ml SCF, 100ng/ml FLT3L). The rest (aspirated cells) was delivered
to the 6 mm x 15 mm petri dishes with 6 ml of medium. The 6 well plates and petri dishes
were rotated and incubated the cultures at 370C, 5% CO2 in a CO2 incubator from
additional 2 days.
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Day 3. The10 ml of the RPMI-1640 (with 10% FBS + 20 mM penicillin/streptomycin) and
20 ng/ml GM-CSF were added to 100 mm petri dishes. The cultures in the petri dishes
were rotated and incubated at 370C and 5% CO2 in an incubator for another 3 days. At day
6, the BMDCs collected from petri dish to 40 ml tube and the adherent cells, were discarded
which contained macrophages for the cells counting/viability. The rest of cells, fresh
medium (10 ml) with 20 ng/ml GM-CSF was added. The fresh media was changed every
2 days.

Day 4. The cells were collected from the 6-well plates, 6 mm petri dishes. These cells were
spin down at 300 x g 8 min at 4 0 C, washed with PBS, re-suspended at concentration 1 x
106/ml in IMDM (with Glutamax, 10%FBS, 100U/ml penicillin, 100mg/ml streptomycin,
100ng/ml SCF, 100ng/ml FLT3L), and 10 ng/ml of IL-5 was added. The concentration of
cells count was 1 x 106/ml during the first media change, and the culture media was
changed every 2 of days.
The part of the mature eosinophils and macrophages were collected at the day 19
for the cell counting, Wright stain, Giemsa stain, and cells’ freezing were performed.

2.2

The Freezing of Bone Marrow Cells Differentiated with IL-5 and GM-CSF

The bone marrow cells (from 6-well plates and 100 mm petri dish, were stimulated with
IL-5 and GM-CSF, respectively) were collected to sterile 15 ml centrifuge tubes and
centrifuged at 40 C for 4 minutes. The cells pellets were re-suspended in the culture
medium; BM cells were stimulated with IL-5 and were re-suspended with 1 ml of IMDM
(the recipe was previously descrabed); BM cells that were stimulated with GM-CSF were
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re-suspended with 1 ml of RPMI-1640 (as previously described) and made a homogeneous
suspension. The cells were counted using a hemocytometer and trypan blue staining
method was used for cell viability. The cells were not adjusted to the cell density as per
required number for cells. Next, the cells were re-suspended with 90% FBS and 10%
DMSO and frozen at -800C for 24 hours.

2.3

Immunostaining and Observation of Bone Marrow Derived Eosinophils and
Bone Marrow Derived Macrophages

Day 1. T-cell concentration was determined before seeding. The cells were seeded at
20000-50000 cells per well into the 12-well slide chamber and topped off with 200µl of
IMDM media or RPMI-1640 media. The cell culture was incubated at 370C, 5% CO2 and
95% humidity for 24 hours.
Day 2. The media was aspirated and washed once with 200 ml of chilled 1 x PBS.
Fixation. The cells were fixed with 4% paraformaldehyde for 15 minutes at room
temperature and washed once with 200 µl of chilled 1 x PBS.
Blocking step. The CSB 200 µl was added for 30 minutes, was kept at room temperature,
and washed with 200 µl of chilled 1 x PBS.
Antibody Incubation, all Steps in the Dark. 50 µl of diluted antibody F4/80, Alexa Fluor
488 tag (1:50 or 1:100), was added to each well (1:100: 1 µl Ab + 99 µl PBS with 5% FBS;
or 0.5 µl Ab +49.5 µl PBS with 5% FBS) and incubated for 1-2 hours at 40 C
Mount for Viewing. The antibody solution was removed, and 12-well chambers were
washed twice (with cold 1 x PBS). Next, the PBS was aspirated completely, the silicone
wells were removed, and cells were allowed to dry. The several drops of VectaShield were
dropped along the center of the slide, the cover slip was placed on top of the VectaShield
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(checked for bubbles) and allowed to harden for 20 minutes. The edges of the coverslip
were fixed. The cells were observed under immunofluorescent microscope.

2.4

Wright Stain Method

EMS Catalog number: 26060.

Seeding Cells in the 12-well Chambers.
The cell concentration was determined before seeding. The cells were seeded at
concentration 20000-50000 per well into the 12-well slide chamber and topped off with
200µl of IMDM with Glutamax, 10%FBS, 100U/ml penicillin, 100mg/ml streptomycin
media (for bone marrow cells differentiated with IL-5) or RPMI-1640 +10% FBS + 20 µM
penicillin/streptomycin media (for bone marrow cells differentiated with GM-CSF). The
cell culture was incubated at 370C, 5% CO2, and 95% humidity for 24 hours. The media
was removed and washed with the PBS once, and dried

Staining: 1.0 ml of the Wright Stain Solution was placed upon the smear for 1-3 minutes.
2.0 ml of distilled water or Phosphate buffer pH 6.5 was added and let stand twice as long
as in step 1. The stained smear was rinsed with water or the Phosphate buffer (pH 6.5) until
the edges showed faintly pinkish-red (or a Giemsa appearance was stained 10 minutes in
one volume Wright stain and 4 volumes Phosphate buffer). The blot was dried very
carefully. Stain may be adjusted by further dilution or in the timing of either before or after
dilution in the above procedure.
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Results: Eosinophils: nucleus – blue; the granules – red to orange; cytoplasm – blue.
Monocytes: nucleus – deep bluish-purple; cytoplasm – pale gray-blue

Evaluation of cell’s Morphology.
1. Was used the light microscope OLYMPUS BH-2; objectives 100x, light source – 6v
20w halogen.
2. For cell culture was used the light microscope 0,3 A Nicon, Japan, magnification 4x,
and 40x.

2.5

Modified Giemsa Protocol.

The cell concentration was determined before seeding. The cells were seeded at
concentration of 20000-50000 per well into the 12-well slide chamber, and topped off with
200µl of IMDM with Glutamax, 10%FBS, 100U/ml penicillin, 100mg/ml streptomycin
media (for bone marrow cells differentiated with IL-5) or RPMI-1640 +10% FBS + 20 µM
penicillin/streptomycin media (for bone marrow cells differentiated with GM-CSF). The
cell culture was incubated at 370C, 5% CO2, and 95% humidity for 24 hours. The media
was removed and washed with the PBS once, and dried
Procedure. 1. Solution A – Fixative: the slide was fixed with the dry cells for 10 seconds
in Solution A.
2. Solution C – Red: the slide was dipped 5 time in Solution C.
3. Solution B – Blue: the slide was dipped 5 times in Solution B.
4. The slides were washed in distilled water and let to air dry.
5. Optionally, the slides were dehydrated in 100% EtOH followed by xylene and mounted
in a synthetic resin.
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Results: Eosinophils: nucleus – blue; cytoplasm – blue; granules – red. The monocytes:
nucleus – purple; cytoplasm – light blue.
Evaluation of cell’s morphology.
1. Was used the light microscope OLYMPUS BH-2; objectives 100x, light source – 6v
20w halogen.
2. For cell culture was used the light microscope 0,3 A Nicon, Japan, magnification 4x,
and 40x.

2.6

Statistical Significance
Statistical significance was calculated using One-Way ANOVA – SigmaPlot 12.0.
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RESULTS
Cell Number and Viability.
The bone marrow cells were extracted from the mice extremities (both femur and
tibia), and we estimated the number of cells and cell viability.

First harvest (October 18,2018).
Cell’s yield. On day 0, bone marrow cells from normal BALB/c, 12 weeks old mice were
counted with yield: 10 x 106 per femur (n=10, 20 femurs) (Fig. 5 A).
On day 4, the expected BM cells showed 1 x 106 (per 6 well dish with IMDM) (n=10).
On day 6, the expected BM cells showed 1,7 x 106 (per 100-mm petri dish) (n=10).

Second harvest (January 18,2019).
Cell yield. On day 0, bone marrow cells from normal BALB/c mice were counted with
yield: 1 x 106 per femur (n=10, 20 femurs, 20 tibia) (Fig. 5 B).

Morphology of the BM Cells (First Harvest).
Fig. 6 represents the typical morphological fashion of bone marrow cells (BM) in culture
with the IMDM/RPMI-1640.
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On day 0, BM cells were seeded into culture petri dishes with RPMI-1640, 10% FBS, 20
µM penicillin/streptomycin, and GM-CSF (20 ng/ml); and 6-well plate with IMDM Glutamax-1, 10% FBS, 100 U/ml penicillin, 10 µg/ml streptomycin, and GM-CSF (20
ng/ml). The cells showed a spherical shape, small diameter, had a good health, and had
precision in cell’s membrane (Fig. 6 A).
On day 6, Immature BM cells were differentiated in the presence of the SCF (100 ng/ml)
and FLT-3L (100 ng/ml) that were added on day 5, with the addition of GM-CSF (20
ng/ml). The cells are represented by both spherical and prolonged morphology, and formed
“colony-like” adherence, however, a lot of cells were floated (Fig. 6 B).
[Second harvest, (January,18, 2019).]

Morphology of the BM Cells (Harvest Two)
On day 0, bone marrow cells from normal BALB/c mice were counted to yield 1 x
106 per femur (n=10, 20 femurs). The femurs from the 12 weeks old mice were very fragile,
which likely were mechanically broken with major cell damages. The diameters of the
bones were narrow and presented some difficulties in fleshing of the marrow, which
resulted in a low number for the BM cells. The lower cell count numbers resulted in a delay
and it avoided counting at day 4 (protocol for BM cells differentiated to eosinophils), and
at day 6 (protocol for BM cells differentiated to the macrophages). Fig. 7 represents the
morphology of the BM cells in culture with the IMDM/RPMI-1640. On day 0, BM cells
were seeded to the petri dishes 100 mm x 15 mm, with the final density 1 x 106 per petri
dish with RPMI-1640, 10% FBS, 20 µM penicillin/streptomycin, SCF (100 ng/ml), FLT3L (100 ng/ml), and GM-CSF (20 ng/ml). Other sample of BM cells were seeded with
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IMDM with Glutamax-1, 10% FBS, 100 u/ml penicillin, 10 µg/ml streptomycin, SCF (100
ng/ml), and FLT-3L (100 ng/ml). The culture media was changed every 2 days. Cells were
small in diameter with visible cell membranes. On day 4, IL-5 10 ng/ml was added to the
culture media. The culture media with BM cells, stimulated with GM-CSF showed less
floating cells (at the days 2, 4, 6, 18). On day 18, before first harvest of cells, the BM cells
stimulated by GM – CSF showed a visible nucleus, healthy phenotype, maturated
morphology, and increased of the population of cells, and clustering (Fig. 7 A). The culture
media with BM cells stimulated with IL-5, continued a high number of floating cells with
a small population of cells without formation of the colonies; however, the nucleus of the
cells appeared with “ring-like” shapes (Fig. 7 B).

Bone Marrow Culture Differentiated with GM-CSF and IL-5 Yields Mature
Eosinophils and Monocyte/Macrophages.
On day 19, bone marrow cells that were grown with RPMI-1640, 10% FBS, 20 µM
penicillin/streptomycin, SCF (100 ng/ml), FLT-3L (100 ng/ml), and GM-CSF (20 ng/ml);
and with IMDM with Glutamax-1, 10% FBS, 100 U/ml penicillin, 10 µg/ml streptomycin,
SCF (100ng/ml), FLT-3L (100ng/ml) and 10 ng/ml of IL-5, were harvested for: 1) Wright
staining; 2) frozen purpose.
The total number of BM cells, differentiated with IL-5, continued 1.7 x 103; and
compared with GM – CSF which was 2.4 x 103 (Fig. 10).
Cells were centrifuged prior to staining, the supernatant was removed and the cell
pellet was re-suspended in (1) 1 ml of RPMP-1640 medium for macrophage-lineage, and
in (2) 1 ml of IMDM medium for eosinophils. For the Giemsa stain, which is used to study
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the adherence of pathogenic bacteria to human cells, one volume of Wright stain and four
volumes Phosphate buffer (pH 6.5.) were used.
The BM cells stimulated by IL-5 had a pinkish cytoplasm and nucleus (Wright stain
and Phosphate buffer, pH 6.5) and others showed a blue nucleus with “ring-like” a structure
(as was said in protocol) and pinkish cytoplasm. The granules (that usually stained a red to
an orange color) have been not identified (Fig. 8B, Fig. 9B).
The monocyte/macrophage lineage was shown with a; purple round nucleus and a
blue-purple cytoplasm. When the Wright stain was used in the absence of Phosphate buffer,
(pH 6.5), the nucleus was stained purple with a light purple cytoplasm. The BM cells, when
differentiated

with

GM-CSF,

were

stained

by

Wright-Giemsa

method,

the

monocyte/macrophage lineage had a blue cytoplasm and deep blue nucleus (Fig. 8A, Fig.
9A).
The aptitude of the BM cells differentiated with IL-5 and GM-CSF was determined
for freezing to store and thaw the cells for letter use. We used the protocol for freezing the
low-density bone marrow fraction (LDBM) of whole bone marrow (WBM) with the
following media: 90% FBS and 10% DMSO. The cells with the total number of BM cells,
differentiated with IL-5, was used at 1.7 x 103; and with GM – CSF was 2.4 x 103. They
were both separately frozen at the - 800 C, for 24 hours. Then, cells were thawed and
cultured with same medium; phenotypically mature eosinophils were seeded with IMDM
with Glutamax-1, 10% FBS, 100 U/ml penicillin, 10 µg/ml streptomycin, SCF (100 ng/ml),
FLT-3L (100 ng/ml) and 10 ng/ml of IL-5; and macrophages were seeded with RPMI1640, 10% FBS, 20 µM penicillin/streptomycin, SCF (100 ng/ml), FLT-3L (100 ng/ml),
and GM-CSF (20 ng/ml) (Fig. 10).
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We found a significant difference between the cells’ growth after the thawing, at
day 6. The cells did not grow appropriately, the cells did not form colonies, the stacked
cells showed devastated cytoplasm, and floating cells significant number were present.
Thus, the study demonstrated that the BM cells differentiated to the eosinophils and
macrophages cannot be used effectively.

High Purity of Differentiation of the BM Cells to the Eosinophil Lineage (IL-5) and
Macrophages (GM-CSF).
The purification of culture cells was evaluated for the IL-5 and GM-CSF; turned
cells into eosinophils and macrophages, respectively.
The Wright/Giemsa stains showed the differences of the BM cells to the two
lineages; i.e, eosinophils (by IL-5) and macrophages (by GM – CSF). The cells show
mature signs or “ring-like” nuclei for the eosinophils and purple, round-like nuclei for the
macrophages.
Thus, the cell’s culture can provide optimal conditions for specific growth with
high purity for eosinophils when most cells showed cells colonies, cell spreading and “ringlike” structure of the nucleus at day 30 (Fig. 11A).
For the BM cells with GM-CSF, multiple cells clusters were shown during
differentiation with sign expand and growth. Thus, high purity for differentiated
macrophages was observed at day 19 (Fig. 11B).
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Culture System Optimization with 60mm x 15 mm Petri Dishes.
The first experiment with differentiation BM cells to eosinophil and macrophages
showed the differences in cells colonies and the number of cells depended on the diameter
of the culture dishes. The highest number of colonies of eosinophils were observed with
the 60 x 15 mm petri dishes. However, 6-well plates demonstrated satisfactory results
(Fig 12).
The differentiation of BM cells to macrophages with the 60 x 15 mm petri dish
were found to be equally sufficient. However, the growth of the BM cells to macrophages
with 6-well plates showed much better results with purer cultures. Thus, BM cells
stimulated with IL-5 and GM-CSF (separately) showed satisfactory growth with 6-well
plates.
To optimize the what is condition, in culture the cells differentiation, expansion,
robust growth, and colonies formation, the growth factors and cytokines were also studied.
Thus, the decrease in the number (10%) of colonies depended on the absence of
FLT3L (3 weeks x 2 times, 2 weeks x 1 time), following the disappearance of SCF.
Between day 40 and day 60, the colonies were reduced approximately one-third. The
absence of IL-5, increased the speed for colonies of eosinophils death (Fig. 14). However,
the colonies growth and expansion were improved by adding FLT3L, SCF, and IL-5.
The same growth factors impacted the colonies of macrophages, too, which showed
rapid decrease in colonies at days 38 – 50 and the absence of the GM-CSF negatively
impacted the cell culture (Fig.13).
After 50 days of growth of mature eosinophils, eosinophils developed a bi-lobed
nucleus (Fig. 15, Fig.16 A and B). The colonies of eosinophils within the bottom of the
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petri dish were redistributed to the periphery. The colonies were relatively proportional to
the cells’ growth and appeared to be liner-like or round-like. The first appearance of
different patterns of the growth of eosinophils occurred in the absence of IL-5 (Fig.13, 15).
The differences between of macrophages and patterns of colonies development
were without any differentiating features (Fig. 14, Fig.15).

The Formation of Eosinophil Extracellular Trap (EET) by BM cells Stimulated by
IL-5
Next, a new pattern of BM cells was stimulated with IL-5, two months after
extraction of the BM cells. Without the addition and IL-5 within two weeks following,
morphological changes of eosinophils and new patterns of cells’ growth were found.
Eosinophils moved toward the periphery of the petri dishes and showed linear or circlelike formation of growth (Fig.17). With magnification (40 x, Nikon) the following
observation were made: the cells with the different nucleus (more lobular structure or
round), debris that reflected the lighting of the light microscope with “fluorescent”-like
reflections, and cellular debris.
The patterns of the cells’ growth did not fade with time and increased in density,
and “attracted” more eosinophils (Fig. 17). Morphological changes of cells included: (1)
The eosinophils showed the holes in cell surfaces (Fig. 18, top photos, arrow-pointer); (2)
The nucleus of the eosinophils were “de-condensed”, which showed the round shapes (Fig.
18, lower photos); (3) The eosinophils demonstrated the protrusions of the PM with
concentration of orange to yellowish lighting close to the borders of the PM (Fig. 20); (4)
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The eosinophils appeared in a new fashion of their morphology that is dendrite-like sprouts
and were visible by modified Giemsa staining (Fig. 22).
The staining showed the new sign of the extracellular trap: (Fig 18, lower, right
images; Fig 19), (modified Giemsa). The eosinophil-derived granules were orange to
yellow and have double-like structures. The areas within the EETs were abundant with the
cell-derived granules
Eosinophils, differentiated from BM cells of mouse within EETs, were able to
express the F/80 protein (Fig.21, C). Thus, eosinophils expressed F4/80 were in close
intensity of expression of F4/80 within RAW cells (control, Fig. 21, A), and as well as
within mouse BM-differentiated macrophages (Fig.21, B). The expression of F4/80
proteins were visible through immunofluorescent microscopy.
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A.

B.

Figure 5: Schematic of the medium culture for differentiation of eosinophils and
macrophages from BM cells
A. Schematic of the medium culture for BM cells, differentiated with GM-CSF (day 0), and
IL-5 (day 9). B. Schematic of the medium culture for BM cells, differentiated with GM-CSF
(day 0), and IL-5 (day 4).
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A.

B.

Figure 6: Morphology of Murine BM Cells at Different Days of the Stimulation by
GM-CSF (Harvest 1, October 18, 2018)
Freshly isolated BM cells were cultured in the growth medium RPMI-1640 with 10%
FBS containing 20ng/ml rm GM-CSF. A. Bone marrow cells, day 0. B. Bone marrow
cells, day 6, colonies formation and cells adherences were observed (indicate by arrow).
The SCF and FLT3L were added at 10 ng/ml (day 5). The population of the cells was
increased. Magnification E 4/0.10 -1601(left side), and 40/0.55 LWD -160/1.2 (right
side). 0.3 A, Nikon.
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A.

B.

Figure 7: Morphology of Murine BM Cells at day 18 of the Stimulation by GM-CSF
and day 14 of Stimulation by IL-5 (Harvest 2, January 18, 2019)
BM cells were cultured in the growth medium RPMI-1640 with 10% FBS containing 20
ng/ml rmGM-CSF, 100 ng/ml SCF and 100 ng/ml FLT3L. Population of the cells was
increased A); and with IMDM, 10% FBS, 100 ng/ml SCF, 100 ng/ml FLT3L and 10
ng/ml of IL-5. The cell’s nucleus represents a “ring-like” structure B). Magnification: E
4/0.10, 1601 (left side), and 40/0.55 LWD -160/1.2 (right side). 0.3 A, Nikon.
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BM derived eosinophils
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Figure 8: BM - Derived Eosinophils and Macrophages, first Wright Stain.
A. Macrophages; B. Eosinophils. Magnification 40/0.55 LWD -160/1.2. 0.3 A, Nikon
(right photos); A, B. Magnification x 100; 1.25011. OLYNMPUS, Japan. 118633 (left
photos); Magnification: E 4/0.10, 1601 (right side).
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A.

B.

Figure 9: Wright Stained and Modified Giemsa Stained Phenotype of BM - Derived
Macrophages and Eosinophils
A. Macrophages ; B. Eosinophils. Magnification x 100; 1.25011. OLYMPUS, Japan.
118633 (left photos).
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Figure 10: Day 19. Differentiated Bone Marrow Cells Cultured from Frozen Bone
Marrow Cells in a Six-Well Plate
Eosinophils and macrophages were exposed to - 800 C for 24 hours and thawed with
same medium. The graph represents the number of cells after second exchange the media
(day 4). Data A and B presented as the mean +/- SD, n=5. **P < 0.01.
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Figure 11: Selective Culturing Procedure
A. Eosinophils are stimulated by IL-5. B. Macrophages are stimulated by GM-CSF.
Magnification E 4/ 0.10 (left); 40/0.55 LWD -160/1.2. 0.3 A, Nikon (right photos);
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Figure 12: BM cells with IL-5 and GM-CSF
A. BM cells with IL-5; B. BM cells with GM-SCF. Culture System can be Performed in
60×15 mm, Petri Dishes.
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Figure 13: FLT3L, SCF, IL-5 and GM-CSF are produced for optimal growth and
expansion of cells
FlT3L, SCF stimulation, sufficiently activated the cell colonies’ growth. IL-5 supported
the differentiation and rapid expansion of eosinophils. Absence of IL-5 impacted the
population of macrophages.
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A.

B.

Figure 14: Comparison of Eosinophils and Macrophages Growth depend on
Stimulation by FLT3L, SCF, and IL-5 (Eosinophils) or GM-CSF (Macrophages)
A. BM cells stimulated by IL-5; right image is active mitosis of BM cells stimulated by
IL-5 (day 14); middle image is robust cells growth in response to growth factors (GFs)
and IL-5 (day 30); and left image is sharp decrease of cells growth in response to absence
of GFs, and IL-5 (day 55). B. Poor growth of BM cells stimulated by GM-CSF in
response to absence of the GFs and GM-CSF (day 40, second harvest, left image); middle
and right images are positive response to the GFs. Magnification 40/0.55 LWD -160/1.2.
0.3 A, Nikon
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Figure 15: Changing the Morphology and Growth Pattern of Eosinophils
First emergence of the bi-lobed eosinophils and change the growth pattern of eosinophils’
colonies.
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Figure 16: The New, Different Morphology of Eosinophils. Bi – Lobed
Appearance in vitro
A (upper images); B (lower images). Magnification x 100; 1.25011. OLYNMPUS, Japan.
118633
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Fig. 16. B. The New, Different Morphology of Eosinophils. Bi – Lobed Appearance
in vitro. (lower images)
Magnification x 100; 1.25011. OLYNMPUS, Japan. 118633
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NC

NC + EET

EET

Figure 17: BM Cells Treated by IL-5 Generate Eosinophil Extracellular Traps
Magnification 40/0.55 LWD -160/1.2. 0.3 A, Nikon. The Changes of eosinophils within
EETs. 1. NC (normal cells) with “ring – like” structure of the nucleus, the debris of cells
are absenced; NC + EET (Eosinophil extracellular trap,) represents the cells with the
decondensed nucleus, cellular debris are visible on the left site of the image, the right site
the image are cells with “ring-like” structure of nucleus and cellular debris are not visible;
EET represents the cells with the decondensed nucleus, and cellular debris are visible.
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Figure 18:The Changes of eosinophils within EETs.
Magnification 40/0.55 LWD -160/1.2. 0.3 A, Nikon; Magnification x 100; 1.25011.
OLYNMPUS, Japan. 118633. The eosinophils’ nucleus within the EETs showed the
transmission from “ring-like”, bi-lobed structure to the round and decondensed shape
(lower images). The plasma membrane protrusions showed concentration of granules
within the border of PM that were visible with modified Giemsa staining (lower images).
Upper images show by arrow the holes within the plasma membrane (PM).
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Figure 19: Characteristic of EETosis-induced Intact Release of Granules by
Eosinophils
The released granules from eosinophils that were stained by modified Giemsa, showed
double-spherical structures in vitro. Granules showed the clustering-like characteristic.
Magnification x 100; 1.25011. OLYNMPUS, Japan. 11863
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A.

B.

Figure 20: EETs Produce Morphological Changes in Eosinophils (Modified Giemsa
Stain Method)
The both panels: upper and lower show the deformation of eosinophils and origin of
protrusions of the PM. The yellow-to orange lighting around the PM from the side of the
cytoplasm resemble the eosinophil-derived granules. Magnification x 100; 1.25011.
OLYNMPUS, Japan. 118633.
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A

B

C

Figure 21: The expression of F4/80 by BM cells differentiated with IL-5 or GM-CSF
A. RAW cells (control), treated with F4/80 (GFP). B. BM cells differentiated with GM –
CSFF, treated with F4/80 (GFP). C. BM cells differentiated with IL-5, treated with F4/80
(GFP).
According to Choi et al., (2018), EET-treated epithelial cells exhibited greater fluorescence
than untreated cells. EETs increase epithelial permeability.
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Figure 22: The presentation of eosinophil’s dendrite-like appendixes of cytoplasm
Magnification x 100; 1.25011. OLYNMPUS, Japan. 118633.
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DISCUSSION
In this work, we have demonstrated the differentiation of eosinophils and
macrophages from Bone Marrow (BM) cells of mice and extended cell cultures for six to
nine months. For this purpose, previously tested protocols by Dyer et al, 2008; Lu and
Rothenberg, 2014; Madaan et al, 2013; Schollaert et al, 2014 were used. Previously it was
mentioned that after stimulation of the BM cells by IL-5 within 4 days, a significant
increase in the eosinophils growth should occur after 12 days by IL-5 and stimulation
should not be observed (Schollaert et al, 2014). Thus, comparing and contrasting the
protocols, mouse BM cells were cultured with SCF and FLT3L, followed by amplification
of IL-5 and inoculation with viruses around 18 days. The protocols that effectively
demonstrated the differentiation of mouse BM cells to eosinophils require whole bone
marrow cells, SCF, FLT4L to provide morphologically mature eosinophils, prior to
stimulation of the cells by IL-5 (Dyer et al, 2013). The protocols are effective for
differentiation of the mature eosinophils and to study their function. Previously, Kimberly
et al, 2008, argued about the important function FLT3L has to influence the growth of the
eosinophils’ progenitor. Recently, Schollaert et al, 2014, demonstrated the new protocol
for differentiation of the mature eosinophils with amplification of the IL-5, which is
necessary. The authors mentioned that FLT3L does not show the significant effect for
differentiation of eosinophils and lower doses of SCF is sufficient to promote maturity and
functionally efficient murine eosinophils. Moreover, this study showed that with
stimulation of the BM cells with FLT3L, the response of such cells to the following IL-5
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would be blocked. It was shown that the main function of FLT3L is differentiation of the
lymphoid commitment from hematopoietic progenitors and generation of the dendritic
cells. Also, the previous authors mentioned that: (1) SCF is important for achieving the
mature eosinophils with the certain function; (2) this growth factor is expensive, and (3)
SCF may stimulate only several eosinophils per low density bone marrow fraction LDBM
cells.
Next, the optimal size for the BM cells culture are the 96-well plates, as well as
24-well and 6-well plates. The LDBM cells can be frozen and thawed which using of the
96-well plate without a significant decrease in the number of cells. Previously, Wen et al,
2012; Schollaert et al, 2014, mentioned that cultured eosinophils of mouse expressed
CCL11 (ligand CCR3) and CCR3, are specific markers for such cells. Murine eosinophils
can express F4/80 as well as macrophages, however, in lower concentrations. The CCR3,
Siglec-8/Siglec-F (mouse), EMR1 (human), F4/80 (mouse), and CD11b (human/mouse)
can be used for identification of the eosinophils (Lin et al, 2005; Lee et al 2012). Our
current study shows similarities between human versus mouse eosinophils and said “ringlike” structure of the murine eosinophils is different from human eosinophils because those
are “bi-lobular”. Moreover, Rudden et al, 2005; Culley et al, 2006, demonstrated the
releasing of the IP-10 during viral-associate infection, and later showed that IP-10 was
released from storage granules. The low level of CCR3 and CXCR4 might be expressed
from isolated humans’ eosinophils (Nagase, et al, 2000). The expression of CXCR4
regulated by IFN-y is the cause for activation of apoptosis by eosinophil and the prevalence
of the Th1 type of immune response. However, IL-5, GM-CSF protect the eosinophils from
apoptosis (Th2 immune response) (Wallen et al, 1991). Wooley mentioned that T-tropic
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HIV-1 used CD4 receptor and CXCR4 as the secondary receptor for the virus entry and
developing productive viral infection within the eosinophils. Dyer et al, 2017,
demonstrated eosinophils are targets for the productive viral infection. The recent studies
argued that activation of eosinophils by IL-5 and IFN-y might activate mitochondrial DNA
without the cell lysis (Ueki et al, 2013). Also, this study observed the eosinophils with
hypereosinophilic syndrome and found the liberation of the extracellular granules that can
be bound to the nuclear DNA or can be free granules. Together with releasing the granules
the de-condensation of the nucleus of eosinophils that are different during apoptosis and
necrosis was found: (1) formation of the holes within the PM of eosinophils; (2) changes
in the bi-lobed nucleus of eosinophils to the single nuclear structure; (3) formation of the
intracellular DNA nets, and (4) following the rupture of the PM with formation of EETs.
The term ETosis-mediated cytolysis results in the liberation of the free granules by
eosinophils (Ueki et al, 2012; Choi et al, 2018). Thus, this “double-edged sword” means
the two different ways of behavior of eosinophils protective against infection and support
the development of infection, and attract more investigators.
Thus, in our study we demonstrated that stimulation of the freshly isolated BM cells
from mice that undergo the long-term incubation with SCF, FLT3L, IL-5, and GM-CSF
showed: (1) the temperature – regimen sensation and features of development; (2)
dependence of BM culture from growth factors and cytokines; (3) phenotype-dependent
aging that influence different “ring-like” morphology; and (4) for environmental properties
of eosinophils obtained in vitro. The BM cells were stimulated by GM-CSF together with
the growth factors, SCF and FLT3L for obtaining macrophage-lineage and with IL-5 and
growth factors for obtaining eosinophils (Fig. 5). At the day 6 in culture, the BM cells
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stimulated with GM-CSF showed “good health”, spherical and prolonged morphology, and
started to form “colony-like” adherence (Fig. 6). A second harvest of the BM cells was
done 3 months later and stimulated with same cytokines (Fig. 5); however, we did not
expect high development and growth cells because of low number of multipotent
progenitors (MPPs).
The BM cells that were stimulated with GM-CSF within 19 days combined with
SCF, FLT3L, and IL-5 (10 days) with of the same growth factors were exposed to Wright
staining and to freezing in - 800 C for 24 hours (Fig. 5). After cells’ staining by Wright
stain according to the standard protocol, it was found the BM cells that were stimulated by
IL-5 showed the “ring-like” nucleus, pinkish cytoplasm was identified, and granules were
not identified (Fig. 8B, Fig. 9B) (as mentioned Lee et al, 2012). The BM cells that were
stimulated by GM-CSF demonstrated purple round nucleus and blue-purple cytoplasm
(according to the protocol of Wright stain) (Fig. 8A, Fig. 9A). When it was stained with
the Wright-Giemsa method (according to protocol), the monocyte/macrophage lineage
showed blue cytoplasm and deep blue nucleus. On day 19 of culture, the BM cells were
differentiated with IL-5, shown 1.7 x 103, and with GM-CSF – 2.4 x 103. Next, according
to Schollaert et al, 2014, the LDBM cells could be frozen and stored. Thus, we used the
protocol, proposed by authors, and had frozen the BM cells stimulated with GM-CSF and
IL-5 for 24 hours in -800C. When cells were thawed, they were cultured using the
corresponding to the cell line the medium (Fig. 5). Thus, we found the big difference
between the cells’ account at day 6 after thawing: cells did not grow appropriately; did not
form colonies; stacked cells showed devastated cytoplasm; and there were a lot of floating
cells (Fig. 10). This is the same pattern we have observed with the changing the
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temperature regimen during the different levels of the nitrogen for RAW 264.7 murine
macrophages. Despite higher cells’ account, BM cells differentiated with GM-CSF were
more damaged and showed the worst culture. Thus, the study demonstrated that the BM
cells differentiated to the eosinophils and macrophages cannot be used effectively after
freezing and our results are different from Schollaert et al, 2014.
Although Schollaert et al, 2014, have shown the optimal number of BM cells with
the use of 96-well plates, 24-well plates and 6-well plates, our experiment demonstrated
the best cells’ growth and development of colonies in 60 x 15 mm petri dish in both lineages
(stimulated by IL-5 and GM-CSF) (Fig. 11, Fig. 12). Thus, unlike Schollaert et al, 2014,
growing and developing the BM cells stimulated by GFs with IL-5 and GM-CSF for long
term, optimal numbers of the eosinophils and macrophages were achieved with a 60 mm
petri dish, and a 6-well plate cannot be used for long-term eosinophil and macrophage
growth.
In a series of studies, the protocols for differentiation of murine BM cells with GFs
and cytokines, as well as some alterations were made toward the GFs were proposed.
However, we did not find the protocol for the long-term of differentiation and growing of
BM cells and the previously demonstrated protocols showed the cell cultures growth
around 18 days. Unlike Schollaert et al, 2014, our issue directly argued that for an
appropriate differentiation and growth of eosinophils FLT3L, SCF, IL-5 are necessary, and
the same GFs and GM-CSF for the macrophages (Fig. 13). In both our experiments, which
were dependent from the dates of harvesting of mice for the BM cells differentiation to
eosinophils and macrophages, we found that: 1) first lowering colonies of cells (10%) of
both differentiated lines were dependent on the absence of the FLT3L (Fig. 13); 2)
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decreasing in 1/3rd of the cells confluence occurred in culture with eosinophils were
dependent on an absence of SCF and IL-5 simultaneously. Moreover, the absence of both
GFs and GM-CSF impacted and devastated the colonies with macrophages (first harvest)
on day 60. Thus, we concluded that BM-differentiated macrophages are more sensitive to
GFs and GM-CSF stimulation, especially for the long-term growth (Fig. 13). However,
which factor kept the eosinophil alive around 252 days? It was possible that BM cells
differentiated with the IL-5 have used the IMDM medium, and macrophages differentiated
with the GM-CSF and used the RPMI-1640 for the cells growth.
Although the protocol that was proposed by Schollaert et al, 2014, did not include
the FLT3L, we had observed the second event when we lost the FLT3L first and lost the
small percentage of the eosinophil confluence in culture resulting in the absence the SCF
and IL-5 (Fig. 14). It was visible how the absence of FLT3L sped up the wasting of the
eosinophils and was the cause for decline of the number and fashion of the macrophages
(Fig. 14). Unlike the previous authors, we concluded that the long-term differentiation and
growth of eosinophils and macrophages are dependent on both FLT3L and IL-5. Moreover,
despite the second absence of the GFs and cytokines, the number of eosinophils was
relatively stable with long-term growth. However, we found a different pattern of
eosinophils’ growth that had been grown with switching the dislocation of cells close to
the wall of the petri dish.
Given our long-term attention toward the eosinophils, we investigated the
dependence of changing morphology of cells toward the aging cells. As Dvarak et al, 1994:
Egesten et al, 1986; Denzler et al, 2000, argued about the “ring-like” structure of
eosinophils, we desired to observe the phenotype of cells with aging and how it was
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different from “mature” eosinophils with 12-14 days. Unlike the mentioned authors, we
observed the development of different shape the nucleus of eosinophils, which was
represented at bi-lobed fashion after 50 days of growth of mature eosinophils (Fig. 16, A
and B). In addition, the number of “ring-like” eosinophils were equal to the “bi-lobed” at
day 70 (Fig. 15). Moreover, eosinophils have the dendrite-like ramifications, and some of
them also have the pinkish staining (Fig. 22). Thus, long-term development of mouse
eosinophils contributes to the different morphology of the cells. The colonies of eosinophils
within the bottom of the petri dish were redistributed to the periphery that were linear-like
or round-like composition of cells.
Next, we evaluated the new pattern of BM cells stimulated with IL-5, two months
after extraction of the BM cells. Previously, Wallen et al, 1991, said that the IL-5 protects
eosinophils from apoptosis, and, probably, our eosinophils survived long-term with the
stimulation by IL-5. Moreover, according to Chelucci et al, 1999, the human eosinophils
in vitro expressed CXCR4, which is a trigger for apoptosis. IL-5 and GM-CSF protect the
eosinophils from apoptosis through downregulation of the CXCR4 (Lopez et al, 1986;
Wallen et al, 1991). Interestingly, IL-5 is the cause for the development of the eosinophil
extracellular traps (EET) in the patients with asthma that include: the liberation of free
extracellular granules, de-condensation of the eosinophil’s nuclear chromatin; changing
the “bi-lobular” nucleus into single, round and wide nuclear structure, disruption of the
nuclear membrane, and releasing eosinophil’s granules that are enveloped by PM
extracellularly (Ueki et al, 2012; Choi et al, 2018). Thus, we desired to evaluate the
mentioned appearances within eosinophil cultures, especially within re-distribution of
clusters of eosinophils.
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Thus, our observation showed that eosinophils were moved toward the periphery
of the petri dishes and represented the linear or circle-like formation of the growth. With
magnification 40/0.55 LWD -160/1.2. 0.3 A, Nikon, the following were visible: the cells
with the different nucleus (more lobular structure or round); debris that reflected the
lighting of the Light microscope with “fluorescent”- like reflections; and cellular “mess”
(Fig. 17). As was described by Ueki et al, 2012, our observation of eosinophils showed:
the holes in cell surfaces (Fig. 18); the nucleus of the most eosinophils “de-condensed”
which showed the round and wide shapes (Fig. 18, lower photos); the eosinophils
demonstrated the protrusions of the PM with concentration of orange to yellowish lighting
of the granules which were found close to the borders of the PM (Fig. 20). The eosinophils
showed the new morphology that are dendrite-like sprouts that have the “pinkish” staining
and were visible by modified Giemsa stain (Fig. 21). Also, those descriptions of changing
of eosinophils’ morphology was mentioned by Choi et al, 2018. Moreover, the
development of EETs increased more than 10% cells “detachment” (Choi et al, 2018). As
was shown in Fig. 15, the eosinophils’ population was not increased with development of
EET and confluence of cells were around 35% in the last two weeks.
The new sign of the extracellular trap was observed: (Fig 18, Fig 19), of the
eosinophil-derived granules that have orange to yellowish coloring, and have double-like
structures. The areas of eosinophils with the EETs were abundant with the cell-derived
granules that were visible because they did not combine with the nuclear DNA, as was
mentioned by Ueki et al, who had described the term EETosis that is different from necrosis
and apoptosis. Thus, results indicate that long-term use of IL-5 as stimulator for survival
of eosinophils through inhibition of the CXCR4 and promote robust growth of eosinophils,
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could be a cause for decline of the number of such cells and through stimulation of the
EETosis in vitro.
Finally, unlike the conclusion of Lin et al, 2005, we found that differentiating of
bmEos was able to express the F4/80 protein in close level to the RAW cells (control) as
well as close to the mouse BM-differentiated macrophages (Fig. 21). This fact supported
the conclusion by Choi et al, 2018, who have mentioned that the cells within EETs
exhibited much greater fluorescence lighting, thus, EETs activate the cellular permeability.
The present data indicates that EETosis activates the expression of the cellular proteins as
was an example F4/80 that has both extracellular domain and domain within PM
(Lin et al, 2005).
Thus, our observations indicated some changes with eosinophils that were
dependent on the long-term stimulation with IL-5. The following were observed: bi-lobular
eosinophils changed the “lobulation” to single, de-condensed nucleus; the eosinophilderived granules released outside of cells, and were visible after the modified Giemsa stain,
that means that granules were not covered by nuclear DNAs that are the sign of EETosis
as was described by Ueki et al, 2012. Moreover, we showed that the EETs-dependent
morphological changes of eosinophils include: (1) the formation of the holes within of the
cell’s surface; (2) EETs-increased cell’s permeability was shown on eosinophils that
expressed the F4/80 proteins that were in close expression such protein by the RAW cells;
and macrophages, as was demonstrated by Choi et al, 2018. Also, the authors mentioned
that cytotoxic granule proteins relative to EETs as well as the EETosis are cause for
developing the inflammation in vivo. The same mechanism of creation of EETs we found
with the long-term of differentiation of the BM cells to the eosinophils by IL-5 in vitro that
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needs more experimental data which might explain more the pathogenic mechanisms of
the inflammation.
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CONCLUSION AND FUTURE IMPLICATIONS

It was first time observation of the mouse BM derived macrophages that were
stimulated with GFs and GM-CSF for 130 days and eosinophils that were stimulated by
IL-5 for 252 days. This study showed the dependence on using FLT3L and SCF and on
growing in the 60 mm petri dishes. Moreover, both cell cultures (macrophages and
eosinophils) did not show the any practical differencyes in freezing – thawing regime. The
mouse BM cells that were differentiated to eosinophils were grown during the 252 days in
the environment, depended on GFs and cytokines and showed the new morphological
properties of eosinophils that had been developed with time. Additionally, eosinophils
displayed bi-lobular nuclei, and dendrite-like changes. Long term of use the IL-5, or
absence of such cytokine, activated the development of the EETs within the culture of
eosinophils that provoked the production of the free granules, decompressed nucleus, and
holes within of the cytoplasm of the cells. EETosis increased the expression of cellular
protein, (e.g. F4/80) within eosinophils and was visible with Immunofluorescent
microscopy with similar concentration when compared to the RAW cells and BM
differentiated macrophages. The development of the EETs as well as usage of the IL-5 kept
the permanent level of eosinophils within a culture that survived the 252 days and were
harvested.
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Taken together, our finding suggests that long-term development of eosinophils,
with amplification of the GFs and cytokines, impacts their “standard” morphology,
produces the new adaptation to the environmental conditions in vitro that might be a model
for the future study and explanation of developing of the pathological disorders in vivo.
The newly described “age-dependent” morphology of bone marrow derived eosinophils of
mouse might be used for study of functions and could be prototype for the explanation why
eosinophils have two opposite functions (e.g. fighting with infection and contribution to
this). The long-term use of IL-5 was cause for the developing EET in vitro and this model
to develop of EETosis can be used in vitro studies. Studies may include the investigation
toxic effects of eosinophil-derived granules, or the investigation in the protein composition
of the nuclear DNA-derived histones which may change the histological structures of the
tissues. Both granules and histones might be studied for better understanding the process
of the loss of connection between the cells within dermo-epidermal junction resulting in
high mortality rate of patients with Bullous Pemphigoid.
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